Approved Research Proposals

Vivli aims to advance human health through clinical research data sharing. One of the key ways we support this is through the Vivli platform, which facilitates data sharing. Vivli platform metrics as of 30 Sep 2025. The metrics are updated quarterly.

The table provides details of approved research proposals that have signed Data Use Agreements.

Data Request IDLead InvestigatorInstitutionResearch Proposal TitleData Contributors
3244Vojtech HuserNational Library of Medicine/NIHIdentification of Research Common Data Elements in HIV/AIDS AbbVie, Pfizer Inc.
3246Dawn FarrellInstitute of Technology TraleeCochrane Review: Interventions for fatigue in inflammatory bowel disease AbbVie
3270Mirjana Stanic BenicUHC RijekaThe impact of biological interventions on health‐related quality of life in adults with Crohn's disease AbbVie, Biogen
3287 Robert AlexanderTakedaIdentification of biomarkers associated with specific sleep variables GlaxoSmithKline
3288Marc-Antoine Sparfel Tours Hospital MIDRA : influence of demographic and environmental factors on anti- tumor necrosis factor efficacy in rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials AbbVie, Pfizer Inc., UCB
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis Suppurativa AbbVie
3321Ewa OlechIQVIAOptimization of lupus trial design based on entry variables GlaxoSmithKline
3361Gustav NilsonneKarolinska InstitutetInterleukin-6 distribution in plasma/serum GlaxoSmithKline, AbbVie
3369Michael WardNIHPredicting Treatment Response to Tumor Necrosis Factor Inhibitors in patients with ankylosing spondylitis AbbVie, Pfizer Inc.
3762Lin WangJohns Hopkins School of Public Health, Johns Hopkins HospitalThe relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer Project Data Sphere, LLC, Pfizer Inc.
3876Changyu ShenBeth Israel Deaconess Medical Center, Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation Daiichi Sankyo, Inc., Boehringer Ingelheim
4036Akira KimataDepartment of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, JapanDabigatran Integrated Analysis Boehringer Ingelheim
4037Karl PeaceJiann-Ping Hsu College of Public Health, Georgia Southern UniversityAssessment of Matching Methods for Causal Analysis Boehringer Ingelheim
4039claire daienCHU lapeyronieNon-MTX-csDMARDs versus MTX in combination with tofacitinib: a post hoc analysis Pfizer Inc.
4041Vivek RudrapatnaUniversity of California, San FranciscoEnhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis Takeda, AbbVie, Johnson & Johnson
4043Janneke van der WoudeDept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The NetherlandsTofacitinib ulcerative colitis Pfizer Inc.
4047Miriam OronSkintelligence ltd.biological drugs data analysis ImmPort (a data-sharing platform funded by the National Institutes of Health)
4113Lesley InkerDivision of Neprology, Tufts Medical CenterChronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) GlaxoSmithKline, Takeda
4115Amir MahabadiUniversity Hospital Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular MedicineImpact of statin therapy on coronary artery calcification volume and density – A meta-analysis of randomized controlled trials Pfizer Inc.
4116Sharon StraussSt. Michael’s HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis AbbVie
4117John FrewRockefeller UniversityPredictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa AbbVie
4118J. David SpenceWestern University, London, ON, CanadaOn-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial Pfizer Inc.
4121Frederikus KlokLeiden University Medical CenterPerformance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation: a post-hoc analysis of the ENGAGE-AF TIMI-48 Study Daiichi Sankyo, Inc.
4275Lisa StampUniversity of Otago, ChristchurchSerum urate as a biomarker in gout: Protocol for individual patient data analysis for OMERACT 2020 Takeda
4319Maria Alice FranzoiJules Bordet InstitutClinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials. Lilly
4324Peng XieInstitute of Neuroscience, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District Chongqing, chinaComparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: an individual patient data meta-analysis Lilly, GlaxoSmithKline, Pfizer Inc.
4326John MarkmanUniversity of RochesterPhenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury Pfizer Inc.
4327Michael SzarekSUNY Downstate Medical CenterAnalysis of Total Events and Hospitalizations in the SPARCL Study Pfizer Inc.
4329, 4048Shomron Ben-HorinSheba Medical Center, Tel- Aviv University, Israel & Sun Yatsen 1st affiliated Hospital, Guangzhou China Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient level meta-analysis of randomized controlled trials - revised Takeda, Biogen, AbbVie, UCB, Johnson & Johnson
4330Laure GossecSorbonne Université, Paris, FranceDomains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i) Pfizer Inc.
4352Stefano BarcoUniversity Medical Center Mainz; Clinic for Angiology ZürichDifferential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trials Daiichi Sankyo, Inc.
4540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial Daiichi Sankyo, Inc.
4541C Elizabeth CaldonGarvan Institute of Medical ResearchTherapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer Pfizer Inc.
4913Susan HalabiDuke UniversitySurrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma Project Data Sphere, LLC, Pfizer Inc.
4915Rachel TomkoMedical University of South CarolinaPredicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy Pfizer Inc.
4917Andrea CiprianiUniversity of Oxford Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-Analysis Lilly, GlaxoSmithKline, Lundbeck
4918Nina HilkensRadboudumc NijmegenBlood pressure variability and cognitive decline Boehringer Ingelheim
4919Hendrik Jan GuchelaarLeiden University Medical Center (LUMC)Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors Pfizer Inc.
4920Gustavo TureckiDouglas Mental Health University InstitutePredicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters Pfizer Inc.
4922, 3274Diane van der WoudeLeiden University Medical CenterEffect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis Pfizer Inc., AbbVie
4926Eva-Maria GamperMedical University InnsbruckComparison of the EORTC QLU-C10D (a cancer-specific utility instrument) with generic utility instruments and development of a comprehensive manual for its use Boehringer Ingelheim
4931Siddharth SinghUniversity of California San DiegoEarly changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trials AbbVie, Takeda
4933Hongxia WangDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePALOMA-2 Data Request for Biomarker Analysis Pfizer Inc.
4949, 3190Vivek RudrapatnaUniversity of California San FranciscoEfficacy of Crohn's Disease Treatment Stratified by Disease Phenotype AbbVie, Takeda, Johnson & Johnson, Biogen, UCB
4950John "Devin" PeipertNorthwestern UniversityJustification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis AbbVie
5073Philip RobinsonUniversity of QueenslandAssessment of treatment outcome with etanercept in nraxSpA
by baseline CRP
Pfizer Inc.
5074Sebastian ZundlerUniversity Hospital Erlangen, Department of Medicine 1Evaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 in ulcerative colitis and Crohn's disease - meta-analysis Takeda
5079Maureen DubreuilBoston University School of MedicineClinical and MRI predictors of Clinical Response in Axial Spondyloarthritis AbbVie
5080Joel SkaistisBeaumont HealthABC-EBUS Boehringer Ingelheim
5086Junko TakeshitaUniversity of PennsylvaniaA Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases Lilly, AbbVie, Regeneron
5095Mathilde NijkeuterUniversity Medical Center UtrechtAssessing bleeding risk in patients with cancer-associated thrombosis Daiichi Sankyo, Inc.
5096Joo Sang LeeSamsung Medical Center, South KoreaHarnessing genetic interactions to advance precision cancer medicine Tempus AI, Inc.
5098Christopher BaethgeDepartment of Psychiatry University of Cologne Medical School(S)SNRI dose response realtionship Lilly
5099Jorge HernandoVall d´Hebron University HospitalImpact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors Pfizer Inc.
5163Susan Bates, MDColumbia University Medical CenterAssessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data Celgene Corporation
5165Byeongzu GhangDivision of Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of KoreaReanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat Takeda
5166Thomas MetkusJohns Hopkins University School of MedicineSevere sepsis in the cardiac intensive care unit: management strategies and outcomes Lilly
5207Fasihul KhanUniversity of Nottingham, UKA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis Boehringer Ingelheim, Johnson & Johnson, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Roche
5209Bruce PerkinsSinai Health System, University of TorontoTRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL: THE TORONTO-MICHIGAN PATIENT-PROVIDER COLLABORATIVE Boehringer Ingelheim
5276Yan LuoKyoto UniversityPredicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis - Luo UCB
5290Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of GI cancers. Lilly, Roche, Boehringer Ingelheim, GlaxoSmithKline
5291Sarah NevittDepartment of Biostatistics, University of Liverpool, United KingdomAntiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis UCB
5292Désirée van der HeijdeLeiden University Medical CenterMeasurement properties of the instruments used in the outcome assessment of axial spondyloarthritis UCB
5294Daniel CaldeiraCCUL - Faculdade de Medicina da Universidade de LisboaThe clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY Boehringer Ingelheim
5325, 5324Daniel GoldenholzBeth Israel Deaconess Medical Center, Harvard Medical SchoolRetrospective analysis of placebo arm data in clinical epilepsy trials -Goldenholz UCB, GlaxoSmithKline
5330Laura BonnettUniversity of LiverpoolModelling seizure rates within clinical trials of antiepileptic drugs - Bonnett UCB
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach - Myasoedova UCB, Roche
5435Matthew GilbertLarner College of Medicine at The University of VermontEffect of Albiglutide on Cardiovascular Outcomes in Older Adults GlaxoSmithKline
5436Adrian WaggUniversity of AlbertaA pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age    
Pfizer Inc.
5456Ramona Belfiore-OshanCritical Path InstituteValidation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy Cure Duchenne
5483David McAllisterUniversity of GlasgowHeterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity (McAllister) Boehringer Ingelheim, Takeda, UCB, Lilly, Roche
5812Yougen WuThe Fifth People's Hospital of Shanghai, Fudan University, Shanghai, ChinaDevelopment and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors Roche
5813Phillip GarfinSeattle Genetics IncEffectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypes (Garfin 11387) Roche
5852Marliese AlexanderPeter MacCallum Cancer CentreInfective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis Roche
5853Florian NaudetUniv Rennes, CHU Rennes, Inserm, CIC 1414 [(Centre d’Investigation Clinique de Rennes)], F- 35000 Rennes, FranceData-sharing and re-analysis for main studies assessed by the European Medicines Agency - a
cross-sectional study on European Public Assessment Reports
AbbVie
5869Alexandra FreemanUniversity of CambridgeMeta-analysis of the adverse effects of trastuzumab in women with breast cancer Roche
5871Nobuhisa KanaharaChiba University Center for Forensic Mental HealthDetermination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects Lilly
5872Yaw NyameUniversity of Washington Medical CenterRepresentation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer Trials Pfizer Inc.
5880Benjamin SchneiderIowa State UniversityOptimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung Cancer Lilly, Roche
5897John PeipertDepartment of Medical Social Sciences, Northwestern University Feinberg School of MedicineFACIT Fatigue in Rheumatoid Arthritis in Pfizer Trials Pfizer Inc.
5901Junhao HuInterdiscipline Research Center on Biology and Chemistry, Chinese Academy of SciencesGC change in COVID-19 patients lung Hannover Medical School
5902Thrasyvoulos TzellosDepartment of Dermatology, Nordland University Hospital, Bodø, NorwayDevelopment and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa AbbVie
5904Saskia MiddeldorpAmsterdam UMC, location AMC, University of AmsterdamHokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism Daiichi Sankyo, Inc.
5921Paul SchulzUniversity of Texas Health Science Center HoustonIdentification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications. Lilly
5924Iris SommerUMCGMeta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies GlaxoSmithKline, AbbVie, Johnson & Johnson
5925Min Hwan KimDivision of Medical Oncology, Yonsei University College of MedicineCDK4/6 inhibitor NLR Pfizer Inc.
5930Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer Roche
5931Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiation Therapy in Triple Negative Breast Cancer Roche
5933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritis. UCB, Lilly, Roche
5940Aziz MezliniMassachusetts General hospital/ Harvard Medical schoolA novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects GlaxoSmithKline, Takeda, AbbVie, Lundbeck, Boehringer Ingelheim, Roche, Johnson & Johnson, UCB
5944Pietro SpitaliLeiden University Medical CenterPrediction of disease progression in Duchenne muscular dystrophy Cure Duchenne
5945Neeraj NarulaMcMaster UniversityPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY Takeda
5948Georgia SalantiInstitute of Social and Preventive Medicine. University of Bern, SwitzerlandHTx project Biogen
5950Shirley WangBrigham and Women's HospitalUnderstanding effectiveness of new drugs in older adults shortly after market entry Boehringer Ingelheim
5951, 4543Mathilde NijkeuterUMC UtrechtINDIVIDUALIZED PREDICTION OF RECURRENCE RISK REDUCTION AND RISK OF BLEEDING WITH EXTENDED ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM v2.0 Daiichi Sankyo, Inc., Boehringer Ingelheim
5959John DennisUniversity of Exeter Medical SchoolStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes Boehringer Ingelheim, Takeda
5960Matt LinnikEli LlillyCovid-19 Pulmonary Gene Expression Analysis Hannover Medical School
5963Elyse KatzDepartment of Defense, USSAMMDAA secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress Disorder Lilly
5968Mehul PatelKing's College Hospital NHS Foundation TrustMethods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH) Takeda, Johnson & Johnson
5974Robert SchoeversUniversity Medical Center Groningen, department of psychiatry, University of Groningen (RUG)Prescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD) Lilly
5981Mark PetersonVertex Pharmaceuticals, Inc.Identifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD) Cure Duchenne, Lilly
5982Matthew BakerStanford UniversityInvestigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response Roche
5984David BakerQueen Mary University of LondonExploring possibilities to improve the risk: benefit balance through analysis of the ocrelizumab phase II extension study Roche
5985, 5327Jose Antonio Pereira da SilvaUniversidade de Coimbra, PortugalLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis AbbVie, UCB, Pfizer Inc., Roche
5988Elad SharonNational Cancer InstituteThe Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes Roche
5989Alexandre BetourneCritical Path InstituteSharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator- Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes AbbVie
5990Yan LuoKyoto UniversityPredicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis AbbVie, Roche
6003Andrea QuattroneMagna Graecia University of Catanzaro, ItalyEvaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trials AbbVie
6004Lily LimRady Faculty of Health Sciences, University of ManitobaIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment Roche
6006Nicholas WhiteMahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol UniversityA Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 Pfizer Inc.
6007Judith GoldsteinJohns Hopkins School of MedicineNational Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) Roche
6008David HsiehUniversity of Texas Southwestern Medical CenterPatterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors Roche
6041Neeraj NarulaHamilton Health SciencesHistologic Predictors of Endoscopic Healing in Crohn's Disease AbbVie
6050Paul CinciripiniUT MD Anderson Cancer CenterSafety and efficacy of smoking cessation treatments in smokers with and without depression Pfizer Inc.
6055, 7744Florian NaudetCHU RennesInferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms BioLINCC (a data-sharing platform funded by the National Institutes of Health), Boehringer Ingelheim, ImmPort (a data-sharing platform funded by the National Institutes of Health), Pfizer Inc., Takeda, AbbVie, Roche, UCB, Lilly, Project Data Sphere
6062Alexander MeiselUniversity Hospital of ZurichNeutrophils, NLR and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations Roche
6063Wiesje van der FlierAmsterdam UMC, VUmcOptimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease GlaxoSmithKline, Lilly, Boehringer Ingelheim, Johnson & Johnson
6064Neeraj NarulaHamilton Health SciencesComparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis Takeda, Johnson & Johnson
6066Vivek SharmaUniversity of LouisvilleEVALUATING THE ASSOCIATION BETWEEN PROTEINURIA AND THROMBOSIS AND ITS PREDICTORS IN PATIENTS TREATED WITH BEVACIZUMAB Roche, Lilly, Boehringer Ingelheim
6104Pratik SinhaDepartment of Anesthesia, Washington UniversityHeterogeneous treatment effects in molecular phenotypes of sepsis Lilly
6464Michael WieseUniversity of South AustraliaIndividualisation of gout flare prophylaxis when initiating urate-lowering therapy Takeda
6471Vincent LantingUniversity of Amsterdam Academic Medical CenterRisk of recurrent venous thromboembolism and bleeding in cancer patients: an individual patient data meta-analysis Pfizer Inc.
6472Soong June BaeGangnam Severance Hospital, Yonsei University College of MedicineImpact of neutrophil to lymphocyte ratio and BMI on prognosis in patients with HER2-positive breast cancer regarding the HER2-targeted therapy Roche
6475Tobias PolakErasmus Medical Center, Erasmus University RotterdamCombining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib Roche
6477Tobias PolakErasmus Medical Center, department of BiostatisticsTositumomab : statistical modeling of expanded access programs and conventional trials GlaxoSmithKline
6482Andreas MonschUniversity Department of Geriatric Medicine FELIX PLATTER, University of Basel, SwitzerlandAnalyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patients Takeda
6483Bharati KumarUniversity of BathEvaluation of available statistical methods performance under non-proportional hazards Lilly, AstraZeneca
6484Ari RosenbergUniversity of ChicagoDeveloping predictive and prognostic Artificial Intelligent (AI) digital biomarkers for soft tissue sarcoma Lilly
6489Line UhrenholtAalborg University HospitalTapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthri-tis: a systematic review of randomised controlled trials
AbbVie
6494Maria Alice FranzoiInstitut Jules BordetImplications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting Lilly
6495, 5485Günter HöglingerDepartment of Neurology, Hanover Medical School, Hanover, Germany Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy AbbVie
6496Neeraj NarulaHamilton Health SciencesEndoscopic Disease Severity and Patient Reported Outcomes in Crohn’s Disease Johnson & Johnson, AbbVie
6498Timo UphausUniversity Medical Center MainzIdentifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring system Boehringer Ingelheim
6499, 5323, 5289Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer_012021 Lilly, Roche, Boehringer Ingelheim, Pfizer Inc., AstraZeneca
6515Leire LeacheNavarre Health Service (Spain)Cochrane systematic review-Pharmacotherapy for hypertension-induced left ventricular hypertrophy Boehringer Ingelheim
6521Ethan AltUniversity of North Carolina at Chapel HillBayesian probability of success for multivariate generalized linear models Biogen
6532Odelia CooperCedars-Sinai Medical CenterA study of how growth hormone treatment affects health outcomes inpatients with noncancerous craniopharyngioma tumors Lilly
6534Diego TosiInstitut du Cancer de Montpellier (ICM), Montpellier, FranceAnalysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatment Lilly
6541Dipak Kotecha University of Birmingham, Institute of cardiovascular sciences Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure Boehringer Ingelheim
6543Andreas MeidHeidelberg University HospitalReproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics? Roche
6544Angela WuOxford UniversityInvestigating the association between smoking cessation and mental health in people with and without psychiatric disorders Pfizer Inc.
6550James BrorsonThe University of ChicagoExamination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence AstraZeneca
6551Siddharth SinghUniversity of California San DiegoPredicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry AbbVie
6593Matthieu RoustitCentre d'Investigation Clinique, Inserm CIC1406 CHU Grenoble AlpesLaboratoire HP2, Inserm UMR 1042 Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes AstraZeneca
6594Manju SubramanianBoston University Medical CenterThe Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis Roche
6601Dan TurnerShaare Zedek Medical Center, The Hebrew University of Jerusalem, IsraelAdaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data AbbVie
6632Luca ValerioCenter for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University MainzHealthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in VTE study. Daiichi Sankyo, Inc.
6633Luca ValerioCenter of Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Department of CardiologyPerformance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study Daiichi Sankyo, Inc.
6641Anna FeeneyMassachusetts General Hospital/ Harvard Medical SchoolAntidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysis Pfizer Inc.
6642Neeraj NarulaHamilton Health SciencesModified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s Disease AbbVie, Takeda, Johnson & Johnson
6686Neeraj NarulaHamilton Health SciencesExtended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool Takeda
6710Gus SlotmanInspira Health Network, Vineland, NJIdentifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality Lilly
6712Yeon-Mok OhAsan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDevelopment and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) GlaxoSmithKline
6716Nigam ShahStanford UniverstyApplying machine learning tools to personalize dabigatran treatment decisions Boehringer Ingelheim
6732Yung-Chuan HuangFu Jen Catholic UniversityDecision Tree Model for Dose Selection in Non-valvular Atrial Fibrillation Patients Boehringer Ingelheim
6734Andreas SuhrbierQIMR Berghofer Medical Research instituteThe K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans Hannover Medical School
6739Rifaquat RahmanDana-Farber/Brigham and Women's Cancer Center (Dana-Farber Cancer Institute)Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma Roche, Project Data Sphere
6740Georgios PaliourasNational Center for Scientific Research "Demokritos", Greecein-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular Dystrophy Cure Duchenne
6758Qian ChenHubei Cancer HospitalRetrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy Roche
6759, 5936Zhi XiaoXiangya Hospital, Central-South UniversityRoles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy Roche
6762, 5935Jian-Guo ZhouSecond Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) Project Data Sphere, Roche, Bristol Myers Squibb
6764Jonathan Bartlett London School of Hygiene and Tropical MedicineHypothetical estimands in clinical trials: an application of causal inference and missing data methods AstraZeneca
6765Dan HanleyJohns Hopkins University Pandemic response COVID-19 Research Collaboration Platform NYU Grossman School of Medicine, Intermountain Healthcare, Washington University, St. Louis, Bassett Medical Center, The Queen's Medical Center, Duke University School of Medicine/Duke University Hospital, University Medical Center, New Orleans
6836Alana RojewskiMedical University of South CarolinaSmoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial Pfizer Inc.
6860Nicholas LangeColumbia University Irving Medical CenterBelatacept in obese kidney transplant recipients Bristol Myers Squibb
6866Andy LimMonash HealthMeta-analysis of early stroke recurrence rate in minor stroke AstraZeneca
6869Zhen LinCo-founder and CEO, Robot Bacon CorporationEvaluating Clinical trial data conventions for the Observational Medical Outcomes Partnership Common Data Model Roche, GlaxoSmithKline, Takeda, AstraZeneca, Ferox Therapeutics
6881, 5484Stefan LeuchtSection for Evidence-based Psychiatry, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Munich, GermanyIndividual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia Lilly
7062Julien EdelineCentre Eugene MarquisPATIENT REPORTED OUTCOME (PRO) AS A PROGNOSTIC MARKER IN PATIENTS TREATED WITH TARGETED THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA (PRO²-HCC) Bristol Myers Squibb
7070Georgios TsakonasKarolinska University Hospital/Karolinska Institutet Anaplastic Lymphoma Kinase- Brain Prognostic Index (ALK-BPI) a novel prognostic score for brain metastasized ALK+ Non Small Cell Lung Cancer (NSCLC) Roche
7072James SignorovitchAnalysis Group, Inc.Development of natural history controls to contextualize clinical trial outcomes of boys with Duchenne muscular dystrophy treated with DS-5141b Cure Duchenne
7074Gregory YH LipUniversity of Liverpool, Liverpool, Merseyside, United KingdomImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes Boehringer Ingelheim
7076Elias ErikssonDept. of Pharmacology, Inst. for Neuroscience and physiology, Sahlgrenska Academy, University of Gothenburg, SwedenPost hoc patient-level analysis of the impact of amitriptyline, selective serotonin reuptake inhibitors, and placebo of individual items of the Hamilton Depression Rating Scale GlaxoSmithKline
7077Neeraj NarulaHamilton Health SciencesDominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease Johnson & Johnson, AbbVie
7078Alberto MartiniUniversity of CincinnatiRole of Body Mass Index and concomitant medication use in metastatic urothelial carcinoma Roche
7101Jason LukeUniversity of Pittsburgh; UPMC Hillman Cancer CenterAnalysis of gene expression profiles in melanoma tumors exhibiting differential lactate dehydrogenase biomarker levels and correlation with immunotherapy response Bristol Myers Squibb
7104Jakob NäslundUniversity of GothenburgItem-level effects of adjuvant olanzapine and/or olanzapine monotherapy in treatment-resistant depression Lilly
7126Alessio CortelliniImperial College LondonThe predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer Roche
7127Alexa KimballBeth Israel Deaconess Medical CenterEffects of adalimumab on inflammation-associated hematologic abnormalities in patients with Hidradenitis Suppurativa AbbVie
7136Shou-Ching TANGUMMC Cancer Center and Research Inst.Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancer Roche
7140Michael J. SorichFlinders University of South AustraliaEarly markers of clinical outcome to ipilimumab therapy for advanced melanoma Bristol Myers Squibb
7142Sara TedeschiBrigham and Women's HospitalCausal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout Takeda
7143Chaim SingalexperiMindThe effects of systemic anti-infective concomitant medications on progression of neurological diseases GlaxoSmithKline, Lilly, Boehringer Ingelheim, UCB
7144Timothy PerkAIQ SolutionsExternal validation of the AIQ predictive score of clinical benefit using Sodium Fluoride (NaF) position emission tomography/computed tomography (PET/CT) images in metastatic prostate cancer (mPC). Pfizer Inc.
7145Joan BusnerSignant HealthPsychometric evaluation of PANSS in adolescent schizophrenia trials Otsuka Pharmaceuticals
7147Carmela TartagliaUniversity of TorontoExploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumes AbbVie
7156Angelina TjokrowidjajaUniversity of Sydney NHMRC Clinical Trials CentreConcordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis AstraZeneca
7158Neeraj NarulaHamilton Health SciencesPatient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis Takeda
7159, 6634James SignorovitchAnalysis GroupAssociations between steroid treatment, functional outcomes and disease milestones among subgroups of patients with Duchenne muscular dystrophy (DMD) Cure Duchenne
7161Wesley KerrUCLAReal-time monitoring of individual response to antiseizure medication treatment during clinical trials UCB, GlaxoSmithKline, Johnson & Johnson
7162Andrew BottomleyEuropean Organisation for Research and Treatment of Cancer (EORTC)Cancer Clinical Trials Pooling of Quality Life Data (CATAPULT) initiative Bristol Myers Squibb
7163Laura MezquitaHospital Clinic and the Translational Genomics Group at IDIBAPS Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers. Roche, Project Data Sphere
7164Jörg EllingerUniversity Hospital Bonn, GermanyEvaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma Roche
7224Keiichi FujiwaraGynecologic Oncology Trial and Investigation Consortium (GOTIC)Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technology Roche, Boehringer Ingelheim, Lilly
7225Neeraj NarulaHamilton Health SciencesEarly vs. Delayed Response to Vedolizumab in Ulcerative Colitis Takeda
7227Catrin Tudur-SmithUniversity of LiverpoolAdd-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis UCB, GlaxoSmithKline, Johnson & Johnson
7232Neil OxtobyUniversity College LondonIdentification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling Takeda
7241Frederick ReimherrPsychiatric and Behavioral Solutions, LLCRetrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole Otsuka Pharmaceuticals
7243Emanual MaverakisUniversity of California DavisDeveloping Models from Existing Atopic Dermatitis Outcome Data GlaxoSmithKline
7245Manabu TakakiOkayama UniversityClinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan. Otsuka Pharmaceuticals
7274Jun ChenWest China Hospital, Sichuan UniversityEfficacy comparision of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma -- a network meta-analysis GlaxoSmithKline
7277Eric HarveyMMS HoldingsIntegrating clinical data from 2 trials into the International COVID-19 Data Alliance (ICODA) Workbench Roche
7283Franziska MichorDana-Farber Cancer Institute/Harvard UniversityLarge-scale public data reuse to model immunotherapy response and resistance Bristol Myers Squibb
7288Vipual JairathAlimentiv IncPlacebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials AbbVie, Takeda, Johnson & Johnson
7289Gianluca RigatelliAusl5, Rovigo General HospitalOutcomes of Left Main Purcutaneous Coronary Intervention (PCI) across age classes Duke University School of Medicine/Duke University Hospital
7312Marianna Kruithof-de JulioDEPARTMENT FOR BIOMEDICAL RESEARCH (DBMR), UNIVERSITY OF BERN, AND UNIVERSITY HOSPITAL FOR UROLOGY, INSELSPITAL BERNMachine learning for personalized drug response prediction for bladder and prostate cancer patients Tempus AI, Inc.
7317Emanual MaverakisUniversity of California DavisDeveloping Efficacy Assessment Tools from Existing Psoriasis Clinical Trial Outcome Data Lilly
7321Neeraj NarulaHamilton Health SciencesA Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis Pfizer Inc., Johnson & Johnson
7322Zhengfei ZHUFudan University Shanghai Cancer CenterClinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis Roche
7323Toshifumi KishimotoNara Medical UniversityDevelopment of the optimal treatment of Nalmefene in patients with alcohol dependence Otsuka Pharmaceuticals
7325Andreas ArtemiouCardiff University Predicting outcomes (death, survival) of COVID-19 patients on Standard of Care (SoC) . Roche, NYU Grossman School of Medicine, University Medical Center, New Orleans
7379Michele RomoliBufalini HospitalAntithrombotics in patent formane ovale (PFO)-related stroke: a meta-analysis stratified for the risk of paradoxical embolism score (RoPE) Boehringer Ingelheim
7381Tomoya HirotaUniversity of California San FranciscoEarly Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum Disorder Otsuka Pharmaceuticals, Johnson & Johnson
7384Ulrich MansmannDepartment for Medical Information Processing, Biometry, and Epidemiology; Ludwig-Maximilian’s University München; Marchioninistrasse 15 D-81377 MünchenApplication of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials Takeda, Roche, AstraZeneca
7387Neeraj NarulaHamilton Health SciencesComparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease Takeda, AbbVie, Johnson & Johnson
7388Byeongzu GhangDivision of Rheumatology, Jeju National University School of Medicine, Jeju National University HospitalReanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients Takeda
7394, 6117, 5895Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers_092021 Roche
7395Xiaoling ShangShandong UniversitySurvival analysis of advanced lung adenocarcinoma harboring epidermal growth factor receptor gene mutation receiving the combination treatment of atezolizumab, bevacizumab, carboplatin and paclitaxel. Roche
7396Mary Ann LukasGlaxoSmithKlineModeling and Simulation of ambrisentan pharmacokinetics in young children Duke University School of Medicine/Duke University Hospital
7399Yoichi NaitoNational Cancer Center EastCombined analysis of randomized phase III study ANNOUNCE and randomized phase II study exploring olaratumab. Lilly
7400Aryelly RodriguezThe University of EdinburghWhat are the re-identification risk scores of publicly available anonymised clinical trial datasets? GlaxoSmithKline, UCB
7401Scott GarrisonFaculty of Medicine and Dentistry, University of AlbertaRandomized Controlled Trial Data Availability and Re-Analysis Project Roche, University of Washington, Pfizer Inc.
7404Reena KhannaLawson Health Research InstituteA Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled Trials Takeda
7414Nobuyuki HoritaChemotherapy Center, Yokohama City University HospitalProgression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma Roche
7427Joachim TanMonash UniversityDose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis AbbVie, Johnson & Johnson, Roche
7435Noah GoldfarbUniversity of MinnesotaDecision tool for the use of adalimumab for hidradenitis suppurativa AbbVie
7445Catherine ThieblemontInsermEvaluation of surrogate markers in marginal zone lymphoma Roche
7462Junjie ZhuoHainan UniversityAssociations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s Disease AstraZeneca
7492Yang ZhaoNanjing Medical UniversityAn Investigation on the Role of Blood Biomarkers as Predictors for Individualized Treatment Regimen Selection in Non-Small Cell Lung Cancer. Roche
7493Nina HilkensRadboudumc NijmegenBlood pressure variability and progression of white matter hyperintensities after ischemic stroke Boehringer Ingelheim
7495Thomas AntalffySmart Respiratory Products LtdAnalysing Clinical Applicability of CompEx Endpoints AstraZeneca
7498Riccardo PolosaCenter of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of CataniaA Machine Learning approach to improve smoking cessation trials Pfizer Inc.
7501Min-Gul KimJeonbuk National University HospitalCOVID-19 clinical trial data utilization to develop external control datasets in COVID-19 therapeutics development Hospital Universitario Austral, Montreal Heart Institute, University of Minnesota, Lilly, Roche, HCor Research Institute
7503, 6635Leslie PadrnosMayo Clinic Arizonasystematic review and meta-analysis Heme Malignancy VTE anticoagulation Boehringer Ingelheim, Pfizer Inc., Daiichi Sankyo, Inc.
7518Lucio ManentiUNIVERSITY HOSPITAL OF PARMARole of persistent and isolated reduced serum complement 3 (C3) in lupus nephritis Roche
7520Malathi RamJohns Hopkins Bloomberg School of Public HealthACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis University of Kansas Medical Center, Sharp Healthcare, University of Minnesota, Bassett Medical Center
7535Joshua DragoMemorial Sloan Kettering Cancer CenterStatin use and clinical outcomes on ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer Roche
7539Amit EtkinAlto Neuroscience, Inc.Clinical and demographic predictors of antidepressant treatment in patients with major depressive disorder with agomelatine versus vortioxetine Lundbeck
7541Amit EtkinAlto Neuroscience, IncRole of clinical, historical and demographic factors in the response to antidepressants versus placebo Lilly, Takeda
7542Neeraj NarulaHamilton Health SciencesVedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons AbbVie, Takeda
7543Margaret SalisburyVanderbilt University Medical CenterDisease progression modeling to detect treatment effects in pulmonary fibrosis Roche, Boehringer Ingelheim
7544Cynthia ComellaRush University Medical CenterSensory trick and benefit from botulinum toxin in cervical dystonia AbbVie
7549Vipul JairathAlimentiv Inc.Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis AbbVie, Takeda, Johnson & Johnson
7552Anna van EijkLiverpool School of Tropical MedicineImpact of Malaria in Pregnancy on Infants Study Group Pfizer Inc.
7580Hiroyoshi TakeuchiDepartment of Neuropsychiatry, Keio University School of MedicineEffects of gaps in doses between oral and long-acting injectable aripiprazole on clinical outcomes in schizophrenia Otsuka Pharmaceuticals
7581Rustam Al-Shahi SalmanUniversity of EdinburghCollaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) Daiichi Sankyo, Inc.
7583, 5932Youssef Zeidan American University of BeirutEvaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Roche
7587Yashmin KartenCritical Path InstituteModel-Informed Drug Development (MIDD) in Alzheimer's Disease Lilly
7590Noémie LangUniversity Hospitals of Geneva (HUG)FRILLY: a retrospective single center study on Fractionated Rituximab to avoid Lysis Syndrome in Aggressive B-Lymphoma Roche, Project Data Sphere
7591, 7392Neeraj NarulaHamilton Health SciencesPredictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease VERSION 2.0 AbbVie, Takeda, Johnson & Johnson, Pfizer Inc.
7592Alexandre BetourneCritical Path InstituteIntegration of Biogen Rare Disease Data into RDCA-DAP Biogen
7595Ashley HopkinsFlinders UniversityPredicting therapeutic outcomes to immune checkpoint inhibitors used in cancer treatment_012022 Roche
7597Junko TakeshitaUniversity of PennsylvaniaEvaluating Racial and Ethnic Differences in the Quality-of-Life Impact of Atopic Dermatitis Regeneron, Pfizer Inc., Lilly
7598Harry SouthworthData Clarity Consulting LtdStatistical investigation of comorbidities of back pain in the medical history data from clinical trials of healthy subjects GlaxoSmithKline, AstraZeneca
7599Hwanhee HongDuke UniversityCombining data sources to identify effect moderation for personalized mental health treatment Johnson & Johnson, Takeda, Lundbeck
7601Guru SonpavdeAdventHealth Cancer Institute, Orlando, FloridaMathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum immune checkpoint inhibitors Roche
7606Amber SalterUT Southwestern Medical CenterComorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis Roche
7609Joao Pedro FerreiraPorto University The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline GlaxoSmithKline
7620Emilie SbidianUniversity Paris Est Creteil (UPEC)Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials AbbVie, Lilly, Pfizer Inc., Johnson & Johnson, UCB
7621Adam BoxerUCSFBayesian Disease Progression Modeling and Clinical Trial Design for Progressive Supranuclear Palsy - Richardson's Syndrome AbbVie
7654Shirley YuInstitute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, AustraliaUpdate of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis Sanofi
7656Neeraj NarulaHamilton Health SciencesImpact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis Johnson & Johnson, AbbVie, Takeda, Pfizer Inc.
7658Arman SabbaghiStatistics, Purdue UniversityTripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments Sanofi
7660Shirley YuInstitute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, AustraliaPredictors of placebo response to intra-articular therapy in osteoarthritis - an individual patient data meta-analysis Sanofi
7661Baocheng ChangChu Hsien-I Memorial Hospital, Tianjin Medical UniversityEffects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high risk Sanofi
7662Benoit YouUniversité Claude Bernard LyonPrognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) Sanofi
7663, 7385Amit EtkinAlto Neuroscience, Inc.Cognition and clinical factors as predictors of antidepressant treatment outcome in patients with major depressive disorder Takeda, Lundbeck, Lilly
7667Ashley HopkinsFlinders UniversitySummarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Inc., Lilly, Roche, Pfizer Inc., Sanofi, Takeda, Johnson & Johnson, Bayer
7743Caroline QuachCHU Sainte-JustineIs there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis. Sanofi
7758NAHID SULTANAUniversity of SheffieldIndirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) GlaxoSmithKline
7759Tamar OostromThe Ohio State UniversityHeterogenous Effects in Diabetes Mellitus Clinical Trials and Implications for Physician Prescriptions Sanofi, GlaxoSmithKline
7760John (Devin) PeipertNorthwestern UniversityStudy of Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item as a Measure of Treatment Tolerability in Advanced Cancer Patients across Multiple Tumour Sites and Treatment Types Roche, Lilly, Pfizer Inc.
7772Neeraj NarulaHamilton Health SciencesCombined Histologic and Endoscopic Endpoints in Ulcerative Colitis Takeda
7776Stefan LeuchtProfessor Stefan Leucht MD. Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, GermanyAntipsychotic drugs vs. placebo in the treatment of antipsychotic naive and/or first episode children or adolescents with psychosis: A systematic review and meta-analysis of double-blind randomized trials Lilly, Otsuka Pharmaceuticals
7777PAUL AYUKNewcastle-upon-Tyne Hospitals NHS TrustUsing Dabigatran etexilate to prevent blood clots in women after childbirth Boehringer Ingelheim
7779Luís Inês1- Faculty of Health Sciences, University of Beira Interior, Covilhã, PortugalDerivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. AstraZeneca
7782Yang Li Renmin University of China A new covariate randomization method for multi-arm randomized controlled trials GlaxoSmithKline
7785Christian JonassonNordicRWEUsing Norwegian real world data to emulate and reproduce results from oncology clinical trials Roche
7794Joan CARLESVALL D HEBRON INSTITUTE OF ONCOLOGY VALL D'HEBRON UNIVERSITY HOSPITAL Passeig Vall d'Hebron 119-129 08035 BARCELONACo Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy. Sanofi
7797Jörg EllingerDepartment of Urology, University Hospital Bonn, GermanyEvaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma Roche, Pfizer Inc., Project Data Sphere
7801, 6864Yoshie OmachiNational Center of Neurology and Psychiatry (NCNP)Elucidation of the predictive factors for active and placebo drug response on social functioning and quality of life (QOL) in psychiatric illnesses including developmental disorders Lilly, Johnson & Johnson, Shionogi
7804Qingyun LiGenecast Biotechnology Co., LtdAn exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer Roche
7807Hayato NiiyamaSchool of Data Science, Yokohama City University, JapanA Post-hoc Analysis using Secondary Data of Clinical Trial from M14-033 Study to Evaluate Average Treatment Effect and Heterogeneous Treatment Effect of Adalimumab in Maintenance Phase for Patients with Ulcerative Colitis AbbVie
7809David James Pinato Imperial College, London The prognostic impact of early antibiotics exposure on Overall Survival and Progression Free Survival of patients affected by unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab or sorafenib within the IMbrave 150 trial Roche
7810Diego ChowellIcahn School of Medicine at Mount SinaiMachine learning model to predict cancer immunotherapy response Roche
7811Gustavo TureckiDouglas Mental Health University Institute, McGill UniversityUsing Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder Lilly, AbbVie, Takeda, Otsuka Pharmaceuticals
7817Neeraj NarulaHamilton Health SciencesPredictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis GlaxoSmithKline
7818Werner WeitschiesUniversity of Greifswald, Center ofDrug Absorption and TransportDevelopment and improvement of an in vitro tool, which simulates the physiological characteristics of the ascending colon Sanofi
7819Jeanine Roeters van LennepErasmus University Medical CenterEfficacy & Safety of Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors: a Systematic Review and Meta-analysis of Real-World Data Sanofi
7822Linbin Luthe 900th Hospital of PLATrajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment Roche
7823Marc CarrierUniversity of OttawaAnticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review GlaxoSmithKline, Sanofi
7824Feng SunPeking UniversityAn individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patients Daiichi Sankyo, Inc., Roche
7828Sofia RamiroLeiden University Medical CenterSPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials Lilly, Pfizer Inc., UCB, AbbVie, Johnson & Johnson
7830Yi-Wen TsaiInstitute of Health & Welfare Policy, National Yang Ming Chiao Tung University, TaiwanCost effectiveness analysis of atezolizumab plus chemotherapy for untreated extensive stage small cell lung cancer in Asia Roche
7835Hiroyuki KusuharaThe University of TokyoAssessment of the drug-drug interactions risks of drugs based on the clinical data of the plasma biomarkers AbbVie
7840Marco TagliamentoIRCCS Ospedale Policlinico San MartinoClinical Effect of Chemotherapy-Immunotherapy Combination in the First-Line Treatment of Older Patients with Non-Small Cell Lung Cancer Roche
7842Marco TagliamentoIRCCS Ospedale Policlinico San MartinoPooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer Roche
7844Linong JiPeking University People's HospitalRisk stratification and responder identification using a baseline model and a dynamic risk prediction model for GLP-1RA and SGLT2i in T2DM: a machine learning facilitated posthoc analysis of CVOTs GlaxoSmithKline, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Johnson & Johnson
7845Craig NelsonUniversity of California San FranciscoChange in cognition during antidepressant treatment of late life depression Lilly, Lundbeck
7846Samuele CorteseUniversity of Southampton, UKPATIENCE Individual Patient DATa Network Meta-AnalysIs of the Efficacy aNd aCceptability of Attention-Deficit/Hyperactivity Disorder (ADHD) mEdication AbbVie, Johnson & Johnson, Lilly, Takeda
7848Jennifer LundDepartment of Epidemiology, University of North Carolina at Chapel HillImproving Colon Cancer Therapy Decisions by Extending Trial Representation Sanofi
7849Igor StojkovPaul-Ehrlich-InstitutDeterminants of study design for vaccines against opportunistic bacterial infections: a proof-of-concept for data-driven, individual patient data (IPD) analyses. Sanofi
7850Vipul Jairath Departments of Medicine (Division of Gastroenterology) and cross-appointment to Epidemiology and Biostatistics at The University of Western OntarioImpact of concomitant baseline medication, advanced age and racial differences on efficacy of biologics and small molecules for Inflammatory Bowel Disease Johnson & Johnson, Takeda, UCB, Pfizer Inc., AbbVie
7854Vipul Jairath Departments of Medicine (Division of Gastroenterology) and cross-appointment to Epidemiology and Biostatistics at The University of Western OntarioEfficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials Pfizer Inc., Johnson & Johnson, AbbVie, Takeda
7856Evandro de AzambujaInstitut Jules Bordet, Brussels, BelgiumMetastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival Roche
7857Rentao Yuthe First Affiliated Hospital of Chongqing Medical UniversityCutaneous immune-related adverse events of immunotherapy medications in the treatment of cancers and association with survival. Roche, Daiichi Sankyo, Inc.
7858Jie Zha Department of Hematology, The First Affiliated and Institute of Hematology, School of Medicine, Xiamen UniversityRetrospective cohort study with internal and external validation of a predictive tool for POD24 risk assessment in follicular lymphoma patients Roche
7860Kemi Williams54geneUNITY Global Study Nigeria Datasets Certara
7868Anne-Marie DingemansErasmus MC University Medical CenterPredictive clinical characteristics for weight gain in patients treated with alectinib Roche
7872Dorra BouazziDepartment of Dermatology, Zealand University HospitalHidradenitis Suppurativa – a collaborative study of subtypes AbbVie
7873Xue YangBeijing Cancer HospitalCrizotinib followed by alectinib vs alectinib alone: analysis of treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) -rearrangement Roche
7874Chiara Alessandra CellaIstituto Europeo di OncologiaAddressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials. Pfizer Inc.
7875Marco ValgimigliCardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) Sanofi
7882José González-GomarizFIMAStudy of the expression of several cytokines related with the survival in cancer melanoma patients Bristol Myers Squibb
8052Wataru FukuokayaThe Jikei University School of MedicineAssociation of serum magnesium levels with the effectiveness of atezolizumab in advanced urothelial carcinoma Roche
8053Alexander G MathioudakisManchester University NHS Foundation TrustICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease: randomised COntrolled trials individual participant Data re-Evaluation. GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca
8056Ashley HopkinsFlinders UniversitySummarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of avaliable clinical trial individual-participant data Roche
8058Howard SmithPulmonary Vascular Disease Unit, Royal Hallamshire, Sheffield Teaching HospitalsAn individual patient data meta-analysis of clinical endpoints in pulmonary hypertension with interstitial lung disease (PH-ILD) Boehringer Ingelheim, Johnson & Johnson
8175Guoxing WanHubei University of MedicineEfficacy and safety of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade Roche
8180Sheng LuoDuke UniversityClinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer Daiichi Sankyo, Inc., Roche, Lilly, Pfizer Inc.
8236Gao-Jun TengZhongda Hospital, Southeast UniversityThe role of prior transarterial chemoembolization in atezolizumab plus bevacizumab in hepatocellular carcinoma Roche
8244Frank DoyleRoyal College of Surgeons IrelandDo psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes GlaxoSmithKline, Lilly, Pfizer Inc., Takeda
8263George NtaiosUniversity of Thesaly, Larissa, GreeceRisk of myocardial infarction in patients with paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient data meta-analysis Boehringer Ingelheim, Daiichi Sankyo, Inc.
8266Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityThe prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis Takeda
8287Damian J. RalserDepartment of Gynecology and Gynecological Oncology, University Medical Center Bonn (UKB), Bonn, Germany & Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, GermanyEvaluation of the easy-to-implement modified Glasgow prognostic score (mGPS) in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer in the KATE2 clinical trial Roche
8294Neeraj NarulaHamilton Health SciencesExtended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib Pfizer Inc.
8315Chiara TaniAzienda Ospedaliero Universitaria Pisana, University of PisaEvaluation of gender differences in the efficacy and safety of belimumab in the treatment of active systemic lupus erythematosus GlaxoSmithKline
8316Vipul JairathAlimentivCorrelation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn’s Disease Pfizer Inc., Takeda, Johnson & Johnson, AbbVie
8324Jeroen DekervelUZ Leuven, Leuven, BelgiumResponse Evaluation Criteria in Solid Tumors (RECIST) vs modified RECIST response durability in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Roche
8325Xiaodan TangNorthwestern UniversityDoes scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory AbbVie
8327Eva HosterDepartment for Medical Information Processing, Biometry, and Epidemiology Ludwig-Maximilian University (LMU) MunichConstructing estimands for overall survival within causal frame work for dynamic treatment schemes in oncology: Simulation and a clinical trial example Roche
8342, 7444GUS SLOTMANINSPIRA HEALTH NETWORK, VINELAND, NJIDENTIFYING TOCILIZUMAB-RESPONSIVE COVID-19 PATIENTS FROM COVACTA, EMPACTA, AND REMDACTA RCTS PRE-RANDOMIZATION DATA Roche
8344Xiaoling ShangShandong UniversityA clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide Roche
8347Hong Jae ChonCHA Bundang Medical CenterThyroid irAE correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Roche
8349Nqoba TsabedzeUniversity of WitwatersrandThe efficacy of beta-blockers on morbidity and mortality endpoints in black hypertensive patients: A meta-analysis GlaxoSmithKline
8377Neeraj NarulaHamilton Health SciencesEstimating Differences in the Comparison of Outcomes in Clinical Trials for UC Patients using Patient-Level Data and Aggregated Data: Network Meta-Analysis Takeda, Johnson & Johnson, Pfizer Inc., AbbVie
8427Ahmad AbuhelwaUniversity of SharjahPredictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma Sanofi, Takeda, Johnson & Johnson
8435Hui ZhengChengdu University of Traditional Chinese MedicinePredictors of galcanezumab in the preventive treatment of migraine Lilly
8436David SchadeNM Non profit Society to Prevent Symptomatic Heart DiseaseDevelopment of an Atherosclerosis Reversal Calculator AstraZeneca
8438Sheng LuoDuke UniversityDevelopment of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time AbbVie
8440David SeiffgeInsel Gruppe AGAndexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC AstraZeneca
8442Yi Lisa HwaMayo ClinicBetter outcomes among multiple myeloma patients who are taking beta-blockers while receiving chemotherapy Sanofi
8443Lane DesboroughNudge BG, Inc.Aerobic and Anaerobic Exercise Effects on Blood Glucose and Insulin Jaeb Center for Health Research Foundation, Inc.
8445Kelley KidwellUniversity of MichiganUse of external control with longitudinal data for drug evaluation in Duchenne muscular dystrophy: a Bayesian small sample, sequential, multiple assignment randomized trial design (snSMART) Cure Duchenne, Lilly
8446, 7479, 7075Elias ErikssonNeuroscience and physiologyEfficacy of serotonin reuptake inhibitors in children and adolescents #3 Lilly, GlaxoSmithKline, Pfizer Inc., AbbVie, Lundbeck
8450Dennis McGonagleSection of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients Lilly
8542João Sérgio NevesFaculty of Medicine of University of PortoAlbiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use GlaxoSmithKline
8546Alice AdenisDiabeloopModeling the impact of physical activity, estimated by sensors such as accelerometers and heart rate, on glycemia of Type 1 Diabetes (T1D) patients. Jaeb Center for Health Research Foundation, Inc.
8555Gijsbert StoetUniversity of Essex, Colchester, UKEffects of exercise on blood glucose levels, food intake and insulin use in T1D patients Jaeb Center for Health Research Foundation, Inc.
8557Fan GeGuangzhou Medical UniversityOrgan-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer Roche, Lilly
8558Pablo Guisado VascoHospital Universitario Quironsalud Madrid; Universidad Europea (Madrid)Investigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patients Roche
8559Dag AarslandKing's College LondonPredicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants Lundbeck
8560Emily FoxStanford UniversityHybrid machine learning modeling of Insulin-Glucose dynamics for T1D Jaeb Center for Health Research Foundation, Inc.
8562Raquibul HannanUT Southwestern Medical CenterLong-term outcomes of renal cell carcinoma patients with stable disease following treatment with Ipilimumab and Nivolumab in randomized controlled trial Checkmate 214 Bristol Myers Squibb
8564SANGWOO KIMYonsei Univ. College of MedicineDevelopment of Immune Phenotype-specific Immune Checkpoint Inhibitor Response (anti-programmed death ligand-1) Prediction Algorithm Bristol Myers Squibb
8569GUS SLOTMANInspira Health Network, Vineland, NJUSING PRE-RANDOMIZATION DATA TO IDENTIFY PATIENTS WITH COVID-19 AMONG WHOM FLUVOXAMINE OR IVERMECTIN IMPROVED OUTCOMES Platform Life Sciences
8576Dafne CapelusnikCare and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands Validating a Personalised Ankylosing Spondylitis Metrology Index AbbVie, Johnson & Johnson, Pfizer Inc., UCB, Lilly
8577Yao ZhuFudan University Shanghai Cancer CenterThe impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy Bayer
8581Masahiro TakeuchiThe University of TokyoRepositioning of neurological drug Aripiprazole for Amyotrophic lateral sclerosis (ALS) patients Otsuka Pharmaceuticals
8582David CherneyUniversity Health NetworkModelling Studies to Assess Sodium-Glucose co-Transporter-2 (SGLT2) Inhibition Effects and Kidney Protection in Type 1 Diabetes AstraZeneca, Boehringer Ingelheim
8585Daniel SchachterUnigranrioEfficacy of CGRP monoclonal antibodies in the treatment of medication overuse headache in patients with chronic migraine: A systematic review and meta-analysis Lilly, Lundbeck
8588Wenlong ZhongSun Yat-sen Memorial Hospital of Sun Yat-sen University(SYSU)The influence of antibiotics on survival outcomes for bladder cancer patients being treated with immune checkpoint inhibitor therapy Roche
8591John ReynoldsUniversity of BirminghamPatterns of skin flare in patients with systemic lupus erythematosus AstraZeneca
8593Hyon ChoiMassachusetts General HospitalSerum urate reduction, gout flares and risk of major cardiovascular events during urate-lowering therapy initiation: target trial emulation and self-controlled case series analysis Takeda
8599Marliese AlexanderPeter MacCallum Cancer CentreClinical factors predictive of survival outcomes in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer Takeda, Roche, Pfizer Inc.
8602Robert HamiltonPrincess Margaret Cancer Center, University of TorontoStatin use and prostate cancer outcomes in patients treated in the ARAMIS trial Bayer
8603Wencai JiangChengdu Second People's HospitalPredictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease GlaxoSmithKline
8606Daria IgudesmanAdventHealth Translational Research InstituteEating duration, frequency, and distribution of nutrient intake in association with glycemia, adiposity, and sleep Jaeb Center for Health Research Foundation, Inc.
8609Fredrik SchjesvoldOslo University HospitalPersonalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. Sanofi
8611Adam de HavenonYale UniversityIndex Stroke Severity in Secondary Prevention Trials Boehringer Ingelheim
8615Monia RekikUniversité Laval Using artificial intelligence to predict and prevent physical activity induced hypoglycemia and hyperglycemia in type 1 diabetes Jaeb Center for Health Research Foundation, Inc.
8656Meg JardineThe University of SydneyThe RAAS inhibition in COVID-19 Trialists Collaboration University of Minnesota, Bassett Medical Center
8684José da SilvaCentro Hospitalar e Universitário de Coimbra3Variable and 4Variable Boolean-based remission with Tofacitinib and their association with radiographic outcomes in rheumatoid arthritis Pfizer Inc.
8686Andrea E. van der Meulen - de JongLeiden University Medical CenterAnemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis Pfizer Inc.
8688Grace Lu-YaoThomas Jefferson UniversityRisk of therapy-related adverse events in men on abiraterone or enzalutamide, a IPD meta-analysis of clinical trial data GlaxoSmithKline, Sanofi, Johnson & Johnson
8699Niklas KlümperDepartment of Urology and Pediatric Urology, University Medical Center Bonn (UKB)Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers Roche
8700Leo BuckleyBrigham and Women's HospitalColchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment Montreal Heart Institute
8712Arthur MikhnoMedtronic FoundationT1-DEXI Analysis for Exercise Study Jaeb Center for Health Research Foundation, Inc.
8716Ali CinarIllinois Institute of TechnologyData Analysis, Classification and Model Development using CGM and Physical Activity Data of people with Type 1 Diabetes Jaeb Center for Health Research Foundation, Inc.
8720George NtaiosUniversity of Thessaly, larissa, GreeceAssociation between statin treatment and risk of cardiovascular outcomes and death in patients with atrial fibrillation: an individual patient data meta-analysis Daiichi Sankyo, Inc., Boehringer Ingelheim
8721Jorge BondiaUniversitat Politècnica de ValènciaModeling of exercise and meal disturbances under free-living conditions for improved performance of single- and dual-hormone artificial pancreas systems Jaeb Center for Health Research Foundation, Inc.
8722Daniele RobestiIRCCS Ospedale San RaffaeleAssessing the Androgen indifferent prostate cancer patients reponse to novel antiandrogen-based regimen or taxanes. Johnson & Johnson, Sanofi
8724Joel SkaistisCorewell Health Effect of Tafamidis on Dementia Medication Initiation: A Post-Hoc Analysis of the ATTR-ACT Trial Pfizer Inc.
8728, 5987Glen HazlewoodUniversity of CalgaryDisease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data AbbVie, Lilly, UCB, Roche, Pfizer Inc., Johnson & Johnson, Sanofi
8729Octavian AdamAlbany Medical CollegeTime to Initiation of Symptomatic Treatment in untreated Parkinson Disease Biogen
8747Arsalan ShahidCeADAR: Ireland's Centre for Applied AI at University College DublinUnlocking the Secrets of Glucose Variability: A Machine Learning and Data-Driven Analysis of Hypoglycemia and Hyperglycemia Jaeb Center for Health Research Foundation, Inc.
8750Manit SrisurapanontChiang Mai University Faculty of MedicineDepressive Symptoms Responding to Bupropion: A Differential Item Functioning Approach in Patients with Major Depressive Disorder GlaxoSmithKline
8751Diederik DippelErasmus MC University Medical CenterPrediction of the treatment benefit of intravenous alteplase treatment for acute ischemic stroke Boehringer Ingelheim
8752Michelle CondrenUniversity of OklahomaHelmsley Charitable Trust RFP Jaeb Center for Health Research Foundation, Inc.
8753Yu-Han ChiuHarvard T.H. Chan School of Public HealthDabigatran versus Warfarin in Patients with Atrial Fibrillation: Extending inference from the RE-LY trial to real world target population. Boehringer Ingelheim
8756Eyal Dassau Eli Lilly and CompanyEvaluation of Assessment of insulin utilization in people with type 1 diabetes mellitus using glucose excursions, insulin delivery metrics, and combined with nutrition and exercise information from the T1-DEXI dataset Jaeb Center for Health Research Foundation, Inc.
8757Sandra Tessa HattenhauerMedical Clinic III for Hematology, Oncology, Immune-Oncology, Rheumatology, University Hospital BonnBaseline immune signature score as predictor for response immunotherapy in HCC Roche
8758Michael SzarekCPC Clinical ResearchComparison of RGX-202-01 with ramucirumab or aflibercept in the treatment of patients with recurrent colorectal cancer harboring a RAS mutation Lilly, Sanofi
8760, 4112Florian NaudetCHU Rennes, Clinical Investigation Center INSERM 1414, Department of clinical pharmacology and Adult Psychiatry Tolerability of duloxetine in the elderly and in younger adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo. Lilly, Pfizer Inc., Lundbeck, Takeda, AbbVie
8764Giuseppe CabibboUniversity of PalermoCompeting risk factors in survival analyses for advanced hepatocellular carcinoma outcomes. The key role of liver function and impact of drug class Roche
8765Amit EtkinAlto NeuroscienceUnderstanding individual differences in response to roflumilast in schizophrenia AstraZeneca
8766Catherine RussonExeter Centre of Excellence for Diabetes Research (EXCEED), University of ExeterUsing machine learning methods to predict the risk of exercise-induced hypoglycemia in people with Type 1 diabetes Jaeb Center for Health Research Foundation, Inc.
8767Armando TurchettaMcGill UniversityForecasting recruitments in multicenter clinical trials via the time-dependent Poisson-Gamma model Roche
8768Ryan MizellAdvent HealthPredicting progression in Primary Progressive Multiple Sclerosis with Machine Learning Roche
8769Hyung Seok ParkYonsei University College of Medicine, Cancer Prevention Center, Yonsei Cancer CenterA novel prediction model of poly ADP ribose polymerase (PARP) inhibitor sensitivity using genomic analyses Pfizer Inc.
8773, 6118Roxana MehranThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAAntithrombotic therapy in patients with atrial fibrillation after percutaneouscoronary intervention: a systematic review and individual patient data network meta-analysis Revision of 6118 Boehringer Ingelheim, Daiichi Sankyo, Inc., Bristol Myers Squibb
8774Paco WelsingDept of Rheumatology & Clinical Immunologie, University Medical Center UtrechtUsing the “potential-outcomes framework” to predict added value of more intensive initial therapy for individual early Rheumatoid Arthritis (RA) patients Roche
8802Zhi XiaoXiangya Hospital, Central-South UniversityRoles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis in HER2-positive breast cancer with trastuzumab and pertuzumab therapy Roche
8803Temiloluwa PrioleauEmory UniversityT1-DEXI Analytics Jaeb Center for Health Research Foundation, Inc.
8806Timothy GaultonMass General Hospital, Harvard Medical School Obesity and COVID-19 Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health)
8809Jing YuSichuan universityConstructing a predictive model for lung cancer immunotherapy Tempus AI, Inc.
8815Rayid AbdulqawiKing Faisal Specialist Hospital and Research CentreEffect of Calcium Channel Blocker Therapy in Idiopathic Pulmonary Fibrosis Roche, Boehringer Ingelheim
8828Christopher MoxonUniversity of Glasgow Comparison of histophathology in fatal Covid-19 in Malawi with fatal cases in other settings Hannover Medical School
8833Derek DinartUniversity of Bordeaux, INSERM U1219 & Institut BergoniéOptimal estimation of the number of subjects in clinical trials to improve the quality of clinical research and the development of new treatments for cancer patients Sanofi, Roche, Lilly, Pfizer Inc., Boehringer Ingelheim
8834Xiaohua Douglas ZhangUniversity of KentuckyMarkers derived from continuous glucose monitoring data to guide exercise for T1DM Jaeb Center for Health Research Foundation, Inc.
8837Erin TallonChildren's Mercy Kansas CityDevelopment of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 Diabetes Jaeb Center for Health Research Foundation, Inc.
8839Florencia TettamantiAstraZenecaPredicting survival in chronic lymphocytic leukaemia from measurable residual disease (MRD) kinetics Roche
8842Sheng LuoDuke UniversityClinical and molecular characteristics of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer: a meta-analysis Roche, Pfizer Inc., AstraZeneca
8845Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityBiomarkers for predicting long-term outcomes in ulcerative colitis Takeda, AbbVie, Johnson & Johnson
8846Charles HorsburghBoston University School of Public HealthPredictors of Emergence of Drug Resistance While on Treatment for MDR-TB: A Meta-Analysis Otsuka Pharmaceuticals
8848Wenrui HaoPenn State UniversityDevelop a mathematical model for Alzheimer's disease virtual clinical trial Lilly
8850Changsheng MaBeijing Anzhen HospitalThe impact of malnutrition on the Efficacy and Safety of empagliflozin for people with heart failure Boehringer Ingelheim
8853Guang Sheng LingUniversity of Hong Kong (HKU) Li Ka Shing Faculty of MedicineUsing clinical characteristics of hepatocellular carcinoma (HCC) patients as predictors of their immunotherapy response Roche
8856Fei MaChinese Academy of Medical Sciences and Peking Union Medical CollegeThe impact of human epidermal growth factor receptor 2-low (HER2-low) Expression on the Efficacy of endocrine therapy in Hormone Receptor-positive/HER2-Negative (HR+/HER2-) Breast Cancer Project Data Sphere, Pfizer Inc., Roche, AstraZeneca, Sanofi
8857Zachary Epstein-PetersonMemorial Sloan Kettering Cancer CenterA phase 2 study of Cerdulatinib in treating Cutaneous T-cell Lymphoma (CTCL). AstraZeneca
8860Yutaka ShimazuKyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University HospitalPretreatment lymphocyte counts and free light chain ratio predict the efficacy of elotuzumab against relapsed/ refractory multiple myeloma Bristol Myers Squibb
8864Lisa ChowUniversity of MinnesotaMachine Learning to evaluate glycemic variation with exercise Jaeb Center for Health Research Foundation, Inc.
8865Erin TallonChildren's Mercy Kansas CityData driven approaches to inform the development of eating behavior patterns that promote glycemic management in youth with type 1 diabetes Jaeb Center for Health Research Foundation, Inc.
8873Cristina Soguero RuizKing Juan Carlos UniversityMultimodal data-driven analysis of T1D in pediatrics and adults with machine learning Jaeb Center for Health Research Foundation, Inc.
8874Nicola DalbethUniversity of AucklandAn investigation of remission in patients with gout - efficacy of treatments, prediction of remission and outcomes Takeda
8877Cinzia Del Giovane University Hospital of Modena and Reggio Emilia, Modena, ItalyAntithrombotic therapies for secondary prevention in patients with cryptogenic stroke: a systematic review and network meta-analysis with individual participant data Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Inc.
8879Micaela MorettiniUniversità Poiltecnica delle MarcheDevelopment of a decision support solution to prevent hypoglycemia during and after exercise in T1D Jaeb Center for Health Research Foundation, Inc.
8884Haotian ZouDepartment of Biostatistics and Bioinformatics, Duke University School of MedicineRisk stratification model for predicting risk of recurrence in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients with pathological complete response after neoadjuvant therapy Roche
8885Giacomo CapponUniversity of Padova, Department of Information Engineering (DEI)ReplayBG-E: Expansion of the ReplayBG software to assess exercise-aware treatments of type 1 diabetes Jaeb Center for Health Research Foundation, Inc.
8889Fabricio GarelliNational University of La Plata and CONICET.Modelling short and long-term exercise effect on glucose levels from wearable devices’ signal patterns. Jaeb Center for Health Research Foundation, Inc.
8890Konrad MulrennanAtlantic Technological UniversityDEXTER - Diabetes Exercise Training for Enhanced Regulation Jaeb Center for Health Research Foundation, Inc.
8892Eleonora Maria AielloUniversity of TrentoExercise timing and Circadian Rhythms Jaeb Center for Health Research Foundation, Inc.
8893Eleonora ManzoniUniversity of PadovaDetection and prediction of physical activity in type 1 diabetic subjects Jaeb Center for Health Research Foundation, Inc.
8896Bin CaoChina-Japan Friendship HospitalTreatment of baloxavir marboxil in immunocompromised patients with influenza infection Roche
8897Rebecca DeanUniversity of SussexThe impact of interventions for depression on self-perceptions in young people: A systematic review and meta-analysis GlaxoSmithKline
8903Daniel DeSalvoBaylor College of MedicineDeSalvo - BCM Helmsley RFP Improving Exercise With T1D Jaeb Center for Health Research Foundation, Inc.
8913Thomas HawkeMcMaster UniversityT1-DEXi-T Study: Does exercise training improve the time in range following acute bouts of exercise? Jaeb Center for Health Research Foundation, Inc.
8921Sheng LuoDuke UniversityThe efficacy of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in solid tumor patients with different clinicopathological characteristics: a meta-analysis Daiichi Sankyo, Inc., Roche
8922Tomas KoutnyUniversity of West BohemiaIn-Silico modelling Jaeb Center for Health Research Foundation, Inc.
8924Prajakta Belsare James Madison University Analyzing exercise settings and the impact of various intensities, durations, and types of exercise on people with Type 1 diabetes. Jaeb Center for Health Research Foundation, Inc.
8926Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London, London, UKThe putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials. Roche
8933João Pedro Ferreira Faculty of Medicine of the University of Porto Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozin Boehringer Ingelheim
8937, 6024Cosima LocherUniversity Hospital Zurich of the University of Zurich, SwitzerlandPredictors of placebo response in opioid trials for patients with Chronic Primary Pain – An individual-patient data meta-analysis Pfizer Inc., AbbVie
8944Wesley KerrUniversity of PittsburghEvaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsy GlaxoSmithKline, Johnson & Johnson, UCB
8946Stuart PocockLondon School of Hygiene and Tropical MedicinePatterns of heart failure hospitalisations and cardiovascular death in EMPEROR studies Boehringer Ingelheim
8953Wilson LinSanta Clara UniversityDrivers of Algorithm/Technology Use In Type 1 Diabetes Self-Management Jaeb Center for Health Research Foundation, Inc.
8956Sheng LuoDuke UniversityA Novel Machine Learning-Based Prediction Model for Outcomes in Patients with previously Untreated Diffuse Large B Cell Lymphoma Roche, Project Data Sphere
8957Dean BodenhamImperial College LondonTwo-sample testing for clinical trials data with missing values Bayer
8966Alberico L. CatapanoIRCCS MultiMedicaEffect of lipid-lowering therapies on lipoprotein(a) levels: a meta-analysis of randomized controlled trials Sanofi
8985Joel SkaistisCorewell HealthEffect of tafamidis treatment on total cardiovascular and cerebrovascular events in Transthyretin (TTR) cardiac amyloidosis Pfizer Inc.
8997Lewis CarpenterArcturisThe integration of clinical trial data, real-world evidence, and novel statistical methods to optimise control arm recruitment in relapsed and refractory multiple myeloma Sanofi
9004Limin ZhaoNan Chang UniversityPredicting which breast cancer patients will benefit from Palbiclib treatment through a machine learning model Pfizer Inc.
9007Zhao XingwangJilin UniversityPrediction of hypoglycemia during and after exercise Jaeb Center for Health Research Foundation, Inc.
9012Barry Greenberg MDUniversity of California, San DiegoDevelopment of a Machine Learning Based Score to Predict Risk of Sudden Cardiac Death in Patients with Heart Failure with Preserved Ejection Fraction Boehringer Ingelheim
9016Alane IzuWITS-VIDA Evaluation of Immune Response of 10-valent Pneumococcal Conjugate Vaccine (PCV-10) in HIV infected and uninfected children GlaxoSmithKline
9018Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London (UK) Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from immunotherapy or placebo as sequential therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following chemoradiation therapy: A post-hoc analysis of the PACIFIC trial. AstraZeneca
9019Philip JohnsonUniversity of LiverpoolAssessing the validity of progression-free survival as an endpoint in clinical trials Roche, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, AbbVie
9024Alain AmstutzDivision Clinical Epidemiology, Department Clinical Research, University Hospital BaselEffectiveness and safety of janus kinase inhibitors in hospitalized patients with COVID-19: Systematic review and individual patient data meta-analysis of randomized trials Lilly, IDDO, NIAID (a data-sharing platform funded by the National Institutes of Health)
9053Johanna Elin GehinDepartment of Medical Biochemistry, Oslo University Hospital, Oslo, NorwayPersonalised dosing of certolizumab pegol based on serum concentration in rheumatoid arthritis UCB
9076Alexander TolmachMakeSense Digital Health Ltd.Automatic nutrition assessment based on glucose and insulin data for improvement of carbs counting and investigation of glycemia episodes Jaeb Center for Health Research Foundation, Inc.
9077Anne-Marie WillsMassachusetts General HospitalPredictors of Progressive Supranuclear Palsy (PSP) disease progression AbbVie
9081Kyle GreenwayMcGill UniversityAntidepressant effects of bupropion, varenicline, nicotine replacement therapy, and placebo in tobacco users. Pfizer Inc.
9090Lena FribergUppsala UniversityDose-exposure-response relationships for ceftazidime-avibactam of value to explore dose individualization strategies Pfizer Inc.
9093Ewan GoligherInterdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, CanadaSecondary analysis for estimating heterogeneous treatment effects for the “Drotrecogin Alfa (Activated) in Adults with Septic Shock” trial Lilly
9098Stéphane OudardAssitance Publique des Hôpitaux de ParisExternal validation of a prognostic score for survival in patients with metastatic castration-resistant prostate cancer (CABASCORE) treated with Cabazitaxel. Sanofi
9099Andrew SimsNewcastle upon Tyne Hospitals NHS TrustAn exploration of UK real world evidence and comparison with clinical trial data in supporting evaluation of 4 drugs that have exited the United Kingdom’s Cancer Drugs Fund (CDF). Takeda, Bristol Myers Squibb
9102Joel SkaistisCorewell Health EastEffect of Tafamidis Across the Range of Systolic Function: A Post-Hoc Analysis of the ATTR-ACT Trial Pfizer Inc.
9103JOSE GARCIA-TIRADOUniversity of BernMeal and physical activity behavior in people with type 1 diabetes. A retrospective analysis. Jaeb Center for Health Research Foundation, Inc.
9104Mark WoodwardJanuary AIJanuary AI T1D Jaeb Center for Health Research Foundation, Inc.
9105Nate KowahlVerily Life SciencesVerily_Analysis Jaeb Center for Health Research Foundation, Inc.
9106Nima AghaeepourStanford UniversityIdentifying Subgroups of Patients with Improved Outcomes in Clinical Trials Takeda, AbbVie, Daiichi Sankyo, Inc., Lilly, AstraZeneca, Roche, Sanofi, Pfizer Inc., Montreal Heart Institute, Duke University School of Medicine/Duke University Hospital
9121Vitalay FominY-AI inc. Biomarkers associated with response to monotherapy compared to combination therapy in cancers Roche
9128Pierluigi NavarraCatholic University Medical School, Rome, ItalyA comparison between the assessments of overall response rate carried out by local assessors and a blinded independent central review in oncology trials. Analysis of differences in the assessment conducted at single-patient level. Roche
9129 Yi-Wen TsaiInstitute of Health & Welfare Policy, National Yang Ming Chiao Tung UniversityCost-effectiveness analysis of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: subgroups analyses Roche
9130, 6488Feng SunSchool of public health, Peking UniversityAn individual participant data meta-analysis to evaluate new hypoglycemic drugs (SGLT-2i and DPP-4i) on type 2 diabetes mellitus patient sub-groups Boehringer Ingelheim, Takeda
9132Viola PongratzTechnical University Munich, School of Medicine, NeurologyMonitoring of upper extremity motor function in Multiple Sclerosis (MS): the nine-hole-peg-test in MS revisited Biogen, Roche, Sanofi
9137Ly-Mee YuNuffield Department of Primary Care Health Sciences, University of OxfordLoop Diuretics and Weight Change in Heart Failure: A Meta-Analysis Boehringer Ingelheim, Bayer, GlaxoSmithKline
9141Shujie Yanguniversity of IowaFatty Acid Metabolism, Oxidative phosphorylation, and cholesterol homeostasis pathways in endometrial cancer organoids Tempus AI, Inc.
9228, 8563Kenta YoshidaGenentech/RocheTumor Growth Inhibition-Overall Survival (TGI-OS) model development for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer Pfizer Inc., AstraZeneca
9229Andreas MeidHeidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology, Im Neuenheimer Feld 410 , 69120 Heidelberg, GermanyMAGIC-BULLET - Model-based support of translational steps throughout drug development of antibody-drug conjugates (ADCs) in breast cancer Roche, Daiichi Sankyo, Inc.
9230Erinne WasalskiRutgers UniversityHealth-Related Quality of Life in Breast Cancer Clinical Trials Through the Lens of Race and Ethnicity: The Importance of Understanding the Patient Experience Pfizer Inc., Roche, Lilly, Boehringer Ingelheim, Daiichi Sankyo, Inc., AstraZeneca
9234Matthew ChersichWits Reproductive Health Institute at University of the Witwatersrand - Climate and Health DirectorateDeveloping data science solutions to mitigate the health impacts of climate change in Africa: The Heat and Health African Transdisciplinary Center (HE²AT Center) Boehringer Ingelheim, Sanofi
9235Christian LoodUniversity of WashingtonNeutrophil Lymphocyte Ratio as predictor of treatment response in malignancy Lilly
9236Christian DansereauPerceiv AIValidation of prognostic machine learning tools for forecasting clinical progression to enrich Alzheimer’s disease trials Lilly, AbbVie, Takeda
9239Sheng LuoDuke University Impact of Clinical and Molecular Characteristics of Lymphoma Patients on Prognosis and Potential Mechanisms Roche, GlaxoSmithKline, Takeda
9240Michael KreisslUniversity Hospital Magdeburg"Parameters of Body Composition as prognostic biomarkers in patients with RET-altered thyroid cancer treated with selpercatinib" Post-hoc analysis of the LIBRETTO-001 trial Lilly
9241Amit GargDepartment of Dermatology, Northwell Health, New Hyde Park, NYAssociation between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa AbbVie
9244Kazuki TakadaSaiseikai Fukuoka General Hospital, Fukuoka, JapanImpact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy: A Post Hoc Analysis of IMpower133 Roche
9247Giovanni SebastianiItalian National Council of Research, Institute for Applied Mathematics "Mauro Picone"Hypoglicaemic events risk prediction for type 1 diabetes subjects during physical activity Jaeb Center for Health Research Foundation, Inc.
9250Nan HuFlorida International UniversityMachine learning augmented decision support system for myocardial revascularization treatment plan selection Duke University School of Medicine/Duke University Hospital
9252Danny VolkaertsUniversity Colleges Leuven-Limburg, association of Catholic University Leuven, BelgiumSmart Diabetes Assistent Jaeb Center for Health Research Foundation, Inc.
9253Jiajun YanMcMaster University, Hamilton, Ontario, CanadaStatistical Methods for Analyzing EuroQol 5 Dimension 5 (EQ-5D) in Randomized Clinical Trials Lilly, Takeda, AbbVie, Biogen, Sanofi, Pfizer Inc.
9274Kazuki TakadaSaiseikai Fukuoka General Hospital, Fukuoka, JapanPrognostic Impact of Probiotic Supplementation on the Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with First-Line Atezolizumab: Pooled Analyses of Five Randomized Control Trials Roche
9275Kazuki TakadaSaiseikai Fukuoka General Hospital, Fukuoka, JapanInfluence of Acetaminophen on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: Pooled Data Analyses from Five Randomized Control Trials of First-Line Atezolizumab Roche
9280Nuno Filipe de Sousa ValeFaculty of Medicine, University of PortoPopulation Pharmacokinetic Study involving different formulations of Salbutamol GlaxoSmithKline
9284Jiro McKinnisVirror Health Associative Analysis of Comorbidities and Clinical Variables with Concomitant Presence of Congestive Heart Failure (CHF) in Patients Undergoing Cardiac Catheterization Duke University School of Medicine/Duke University Hospital
9285Mengyi LuNanjing Medical UniversityAssociation of Body Mass Index (BMI) with Prognosis and Safety Profile of Atezolizumab Roche
9286João Sérgio NevesFaculdade de Medicina da Universidade do PortoEffect of Exenatide Across the Spectrum of Ejection Fraction: An analysis from the EXSCEL trial AstraZeneca
9328Sebastian PolakFaculty of Pharmacy, Jagiellonian University Medical College in PolandDeveloping a quantitative base for more effective and individualized ropinirole dosing regimen GlaxoSmithKline
9332Neeraj NarulaHamilton Health SciencesOutcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease Johnson & Johnson, Takeda
9350Lucy VivashMonash UniversityEvaluation of epilepsy-DOOR (Desirability of outcome ranking) as an outcome measure for therapeutic trials in drug resistant epilepsy UCB
9352Sangwoo KimYonsei UniversityConventional genomic predictive markers to immune checkpoint inhibitors are deteriorated in metastatic clear cell renal cell carcinoma Bristol Myers Squibb
9354Li-Xuan QinMemorial Sloan Kettering Cancer CenterTumor Mutational Burden (TMB) Dichotomization for Immunotherapy Outcome Prediction Tempus AI, Inc.
9360Guilherme PolanczykUniversity of Sao Paulo (USP)Moderators of treatment response to stimulants in preschoolers with attention-deficit/hyperactivity disorder: an individual patient data meta-analysis Takeda
9373Amit EtkinAlto Neuroscience, Inc.Cognitive factors as predictors of treatment outcomes in patients with Schizophrenia Boehringer Ingelheim
9377Benjamin Haibe-KainsPrincess Margaret Cancer Centre, University Health NetworkBiomarker discovery for immunotherapy response via pan-cancer and cancer-specific analyses Bristol Myers Squibb
9383João Pedro FerreiraFaculty of Medicine of Porto University Anemia and the Effect of Empagliflozin in HFpEF: findings from EMPEROR-Preserved Boehringer Ingelheim
9384Evyn PetersUniversity Of Saskatchewan Episode duration and severity as predictors of response to desvenlafaxine and placebo in patients with major depressive disorder Pfizer Inc.
9388Ritu LalGEn1E Lifesciences Inc.A Prospective Machine Learning Model for the Identification of Sepsis Endotypes Lilly
9389Sinbad XiaThe Clinical Research Center for Respiratory Diseases of Zhejiang Province, Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of MedicinePredictors of survival in patients with extensive-stage small-cell lung cancer Roche
9390Joseph MerolaThe International Dermatology Outcome Measures Group (IDEOM)Musculoskeletal Symptoms in Hidradenitis Suppurativa AbbVie
9399Philip JohnsonUniversity of LiverpoolA novel, evidence-based approach to clinical trial design in patients with advanced liver cancer (hepatocellular carcinoma); single arm studies with a virtual control group Roche, Boehringer Ingelheim, Bayer, Sanofi, GlaxoSmithKline
9407Josep VehiUniversity of GironaValidation of new exercse models and therapy optimization Jaeb Center for Health Research Foundation, Inc.
9410Abhinav SharmaThe Research Institute of the McGill University Health CentreProprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors on Cardiovascular and Heart Failure Outcomes Pfizer Inc.
9417Vipul JairathAlimentiv Inc. Determining Endoscopic Treatment Response in Ulcerative Colitis and Crohn’s Disease using the Win Probability Approach Johnson & Johnson, AbbVie, Takeda, Pfizer Inc.
9422James SalsburyUniversity of SheffieldDeveloping methodology for a delayed treatment effect present in a survival trial Roche, Bristol Myers Squibb
9433Yang LiSchool of Statistics, Renmin University of ChinaA new Statistical method to balance Social Network Effect and Covariate Effect in Response Adaptive Design GlaxoSmithKline
9434Victor MorenoVictor Moreno, Director of START Madrid-Fundacion Jimenez Diaz (FJD)Retrospective analysis of different doses of atezolizumab in patients with advanced solid tumors Roche
9462Chandra Kanth NageshUniversity of Colorado BoulderAnalysis-of-Type-1-Diabetes Jaeb Center for Health Research Foundation, Inc.
9470Joseph CafazzoToronto General Hospitable Research Institute, University Health NetworkCan we trust GPT-4 Turbo Vision to estimate carbohydrate and caloric content from food images within the broad context of diabetes? Jaeb Center for Health Research Foundation, Inc.
9474Daniel Adam BlancoInari Medical, Inc.Comparative Analysis of Health-Related Quality of Life in Pulmonary Embolism Survivors: PEmb-QoL versus EQ-5D Instruments Daiichi Sankyo, Inc.
9478Lena Friberg Uppsala UniversityStudy on impact of scanning intervals of follow up tumor assessments on Progression Free Survival (PFS) and median PFS for Non-Small Cell Lung Cancer (NSCLC) patients treated with Atezolizumab and Docetaxel. Roche
9480, 6629Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers and patient reported outcomes(PROs) as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) Roche, AstraZeneca, Lilly
9481Nathalie GermainUniversite LavalMelatonin and melatonin receptor agonists for the treatment of sleep disturbances associated with neurocognitive disorders. Takeda
9492, 8697David McAllisterUniversity of GlasgowUnderstanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions Takeda, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lilly, GlaxoSmithKline, Roche, UCB, Sanofi
9731, 7826Carl TuressonLund UniversityEfficacy and safety of TNF inhibitors in seronegative rheumatoid arthritis (update) Johnson & Johnson, Lilly, AbbVie, UCB, Pfizer Inc., Roche
9734James BrorsonThe University of ChicagoMerging data from acute stroke secondary prevention trials for analysis of stroke recurrence risks AstraZeneca
9735Edouard AuclinInstitut BergoniéPrognostic and predictive value of the lung immune prognostic index in patients with advanced small cell lung cancers treated with immune checkpoint inhibitors AstraZeneca, Roche
9736Stefan LeuchtDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of MunichSex differences in antipsychotic side-effects and efficacy in adults with acute exacerbations ofschizophrenia: an individual-participant network meta-analysis Lilly, Servier , Johnson & Johnson, GlaxoSmithKline, AbbVie
9738Onyekachukwu IllohUniversity of Maryland, BaltimoreTranslating Causal Inferences from Randomized & Single-Arm Trials to Externally-Controlled Trials Boehringer Ingelheim
9739David AuerbachSUNY Upstate Medical UniversityAssessment of cardiac electrical function and prevalence of electrocardiographic abnormalities in patients diagnosed with Dravet Syndrome and Lennox-Gastaut Syndrome UCB
9746María Elena Hernando PérezUniversidad Politécnica de MadridPROPHECY: Preprandial Optimized Glucose Prediction with Objective Physical Exercise andCarbohydrate Estimation for Insulin Calculation in Do-it-Yourself Systems Jaeb Center for Health Research Foundation, Inc.
9748Ho So Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong KongCausal inference in retrospective rheumatoid arthritis clinical studies Roche, AbbVie
9764Wenjun Yithe Second Xiangya Hospital of Central South UniversityAssessing the Efficacy of Trastuzumab Emtansine (T-DM1) in Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer Across Varying Hormone Receptor Statuses Roche
9767Rohan KheraYale School of MedicineA computational phenomapping approach to personalize the cardiometabolic benefits of novel glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide agonists in patients with type 2 diabetes mellitus Lilly
9770Massimo GentileHematology Unit of AO CosenzaComparison between Eloquent-3 data with real-life data Bristol Myers Squibb
9771Li YangRenmin University of ChinaCovariate selection and adaptive randomization for sequential experiments Boehringer Ingelheim
9774Aristeidis Katsanos Population Health Research Institute, Hamilton Health Sciences CorporationIndividual Participant Data Meta-Analysis of Randomized Trials of Anticoagulation compared to Antiplatelet Therapy in Patients with Embolic Strokes of Undetermined Source Boehringer Ingelheim
9783Kihyuk ShinPusan National University Yangsan HospitalAge-Stratified Analysis of Acne as an Adverse Event in Patients Treated with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis AbbVie, Pfizer Inc.
9787Hongmei ZhengHubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical and molecular characteristics of human epidermal growth factor receptor 2-positive breast cancers: a meta-analysis Roche
9792maria pia sormaniUniversity of GenoaDefining responders to teriflunomide treatment in Multiple Sclerosis Sanofi
9793Lea DoussetTranslational Research Institute, The University of Queensland, Brisbane, AustraliaImmunotherapy as Prophylaxis: Exploring the Potential Impact on Hyper-Chronic Non-Melanoma Skin Cancers in Retrospective Melanoma Cohorts Bristol Myers Squibb
9797Dr Julian StielsOneTwenty AGAdvanced blood glucose prediction modelling Jaeb Center for Health Research Foundation, Inc.
9809Emma FrölingUniversitätsmedizin Charité Berlin, clincic for psychiatry and psychotherapySystematic Review and Meta-Analysis of Adverse Events During Levetiracetam Therapy UCB
9811, 10462Derek ChuMcMaster University Efficacy and safety of monoclonal antibodies in patients with uncontrolled asthma: a systematic review and network meta-analysis. Roche, GlaxoSmithKline, ImmPort (a data-sharing platform funded by the National Institutes of Health), Johnson & Johnson
9813Sameer JauharKing's College London, Centre for Affective DisordersConducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressants Lundbeck, Takeda, Pfizer Inc., Lilly
9815Tim GretenCenter for Cancer Research, National Cancer Institute, NIHLocoregional therapy impact on immunotherapy Roche
9817Marco GerlingerBarts Cancer Institute, Queen Mary University of London To determine whether Programmed Cell Death Ligand 1 (PDL1) expression in oesophago-gastric cancer differs depending on the tumour site from which the biopsy was taken from. Bristol Myers Squibb
9821Richard FranzeseGSKAssessment of the predictive value of longitudinal circulating tumour deoxyribonucleic acid (ctDNA) dynamics for survival outcomes in non-small-cell lung cancer (NSCLC) Roche
9822Shuhua YiInstitute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeClinical and molecular characteristics of Non-Hodgkin Lymphoma Roche, Takeda
9824Martin OkunFort HealthCareUsing Patient-Level Data from Psoriasis Clinical Trials to Evaluate the Quantitative Relationship between Changes in Skin and Nail Psoriasis Lilly
9826Lorna WheatonUniversity of LeicesterDevelopment and application of new statistical methods for meta-analysis to evaluate treatment effectiveness and surrogate relationships in biomarker subgroups AstraZeneca, Roche
9829Yuanyuan KongBeijing Friendship Hospital, Capital Medical University; Methodological Platform at the National Clinical Research Center for Digestive DiseasesClinical and molecular profiles of Hepatocellular Carcinoma (HCC) treated with combination immunotherapy Roche
9834Tao HanThe First Hospital of China Medical University Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) Bayer, Roche, Sanofi, Boehringer Ingelheim, NIDDK Central
9835Yuya MatsueJuntendo University School of Medicine Graduate School of MedicineImpact of serum hepcidin levels on the efficacy of daprodustat treatment in patients with chronic kidney disease GlaxoSmithKline
9841Anke RichtersThe Netherlands Comprehensive Cancer OrganisationEstimating heterogeneous treatment effects of immunotherapy combination regimens for treatment of advanced/metastatic clear cell renal cell carcinoma: an individual patient data meta-analysis Bristol Myers Squibb
9845Yao ZhuFudan University Shanghai Cancer CenterSerum sodium maintenance levels and outcomes in patients with advanced prostate cancer Bayer, Sanofi
9846Samantha KleinbergStevens Institute of TechnologyExamining Effects of Meals on Glucose in Individuals with Type 1 Diabetes Jaeb Center for Health Research Foundation, Inc.
9848Garrett AshYale School of MedicineDeveloping a pre-trainable foundation time series model for blood glucose prediction among people with type 1 diabetes (T1D) and then applying it to a vulnerable, understudied subset of them Jaeb Center for Health Research Foundation, Inc.
9863Yasuhiro HagiwaraThe University of TokyoDevelopment of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus infected Patients GlaxoSmithKline
9866Weituo ZhangShanghai Jiao Tong University School of Medicinecomparing the methods of selecting and adjusting for covariates in clinical study Lilly
9870Alexandre BetourneCritical Path InsituteIntegration of Biogen Choroideremia Data (NCT03359551 ; NTCNCT03496012) into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) Biogen
9890Jasmine MitchellUniversity of California, Los AngelesThe Effect of Serotonin Reuptake Inhibitors in Metastatic Colorectal Cancer Roche
9906Alessio CortelliniDepartment of Surgery and Cancer Imperial College London, LondonThe putative role of Proton-Pump Inhibitors in patients with Basal Cell Carcinoma treated with vismodegib Roche
9907Akihiro HirakawaTokyo Medical and Dental UniversityDeveloping new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials Montreal Heart Institute, Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health)
9908Haitao ZhaoPeking Union Medical College HospitalThe clinical and prognostic features of acquired resistance to immune-checkpoint inhibitors (ICIs) in Hepatocellular carcinoma (HCC) Roche
9909John ClemmerUniversity of Mississippi Medical CenterImproving heart failure with preserved ejection fraction (HFpEF) treatment using a mathematical model of physiology Boehringer Ingelheim
9910Yang LiRenmin University of China Missing data considerations for patient reported outcome measures in randomized controlled trials Pfizer Inc.
9911Kazuki TakadaSaiseikai Fukuoka General Hospital, Fukuoka, JapanPrognosis of inoperable patients after preoperative atezolizumab administration: A post hoc analysis of Lung Cancer Mutation Consortium (LCMC) 3 Roche
9920Soumyajit RoyUniversity Hospitals Cleveland Medical CenterDoes Timing of Metastatic Presentation (Synchronous versus Asynchronous) Affect Outcome in Advanced Urothelial Carcinoma? Roche, Lilly, AstraZeneca
9924Thomas BüttnerDepartment of Urology and Pediatric Urology, University Hospital BonnEvaluation of Bellmunt Risk Score as a prognostic score in metastatic-castration resistant prostate cancer Johnson & Johnson, Takeda, Sanofi
9939Xiaoyu YanThe Chinese University of Hong KongOrgan specific tumor dynamic predict survival in patients with metastatic breast cancer Roche, Pfizer Inc., Lilly
9960Zhengfei ZhuFudan University Shanghai Cancer CenterOrgan-specific response to atezolizumab and radiotherapy in advanced non-small cell lung cancer patients: a pooled analysis Roche
9962Yukinori OzakiThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchExploring risk factors and prognosis in cancer patients receiving immune checkpoint inhibitor therapy with immune-related adverse events Roche, AstraZeneca, Daiichi Sankyo, Inc., GlaxoSmithKline, Project Data Sphere, ONO
9963Hanna  SuominenThe Australian National UniversityDevelop Type 1 Diabetes Simulators/Models for Exercise in Type 1 Diabetes. Jaeb Center for Health Research Foundation, Inc.
9964João Sérgio NevesFaculdade de Medicina da Universidade do PortoEffects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetes Lilly
9966Luis FarhatUniversity of São Paulo (USP)An evaluation of lack of early improvement and later non-response in early-onset schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Johnson & Johnson, Lilly, Otsuka Pharmaceuticals
10028Hanne VanlucheneAZ DeltaDevelopment of an Inflammatory Bowel Disease (IBD) patient population dashboard to monitor and improve care through machine learning Johnson & Johnson, AbbVie
10030Lihi EderWomen's College Hospital and University of Toronto Exploring Sex-related Mechanisms of Psoriatic Arthritis (PsA) response to advanced therapies (EXSEMP): Individual participant data (IPD) meta-analysis of randomized controlled trials of advanced therapies AbbVie, Johnson & Johnson, Lilly, Pfizer Inc.
10032Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityDynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis Johnson & Johnson, Takeda
10036Akihiro Hirakawa Tokyo Medical and Dental UniversityDevelopment of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease Lilly
10037Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityDynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Crohn's disease Takeda, Johnson & Johnson, AbbVie
10039, 8807Lena FribergUppsala UniversityEvaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma Pfizer Inc.
10046Matthew GalskyIcahn School of Medicine at Mount SinaiExploring C-reactive protein (CRP) dynamics and resistance to immunotherapy in bladder cancer Roche
10047Ramona Belfiore-OshanCritical Path InstituteBayesian item response theory model for the North Star Ambulatory Assessment (NSAA) rating scale Cure Duchenne
10049Dag AarslandKing's College LondonNeutrophil to Lymphocyte Ratio Decrease and Its Association with Clinical Changes in Late-Life Depression Treated with Vortioxetine (Lu AA21004) Lundbeck
10052Yasuhiro HagiwaraThe University of TokyoAdjusting for treatment switching in Oncology Trials: Sensitivity Analysis for Rank-Preserving Structural Failure Time Model Roche, Pfizer Inc.
10054Lisa KochUniversity of Bern Clinic for Diabetology, Endocrinology, Nutritional Medicine and MetabolismFoundational machine learning models for large scale robust modelling of continuous glucose monitoring and activity data Jaeb Center for Health Research Foundation, Inc.
10055Christian Torp-PeteresenNorth Zealand HospitalReanalyzing Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG) using Longitudinal Targeted Maximum Likelihood Estimation (LTMLE) analysis. Boehringer Ingelheim
10090David BakerQueen Mary University of LondonMonitoring white blood cells as an indicator to assess the risks of treatment failure in multiple sclerosis Biogen
10091Jonas SaalUniversity Hospital BonnEstablishing a risk score for Skeletal Related Events (SRE) in patients with cancer Project Data Sphere, Bayer, Johnson & Johnson, Sanofi
10094Sabatina CriscuoloUniversity of Naples Federico IIMachine Learning approach for glycemia prediction in type 1 diabetes Jaeb Center for Health Research Foundation, Inc.
10095Michael GreiciusStanford UniversityRepurposing clinical trial data to understand potential effects of functional unblinding on efficacy of Alzheimer's drug - Gantenerumab  Roche
10098Yohei SekinoDepartment of Urology at Hiroshima UniversityThe potential prognostic value of body mass index in patients with urothelial carcinoma and renal cell carcinoma treated with immunotherapy and tyrosine kinase inhibitor. Roche
10106mehmet fatih özbay Kirsehir Training and Research HospitalExploring the Correlation between Programmed Death-Ligand 1 (PD-L1) Levels and Eosinophilia in Advanced Lung Cancer Patients Treated with Atezolizumab Roche
10112Alessio CortelliniImperial College LondonTP53 missense and truncating mutations may be linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer: a post hoc analysis of the OAK and POPLAR trials. Roche
10116Jean-Pierre FauvelHospices Civils de Lyon, University Claude Bernard Lyon 1Development and validation of clinical prediction tools to estimate all-cause mortality, cardiovascular and renal risk in non-dialysis chronic kidney disease (CKD) patients using machine learning GlaxoSmithKline
10118Neeraj NarulaHamilton Health SciencesAssessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD) AbbVie
10120Pablo BonangelinoUS Food and Drug AdministrationA Bayesian borrowing-by-parts method integrated with propensity score stratification for borrowing adult data for pediatric patients GlaxoSmithKline
10121Itsuki OsawaColumbia University Irving Medical CenterOptimized timing of empagliflozin use for cardiorenal protection: a post-hoc analysis of the EMPA-REG OUTCOME, EMPEROR-REDUCED, and EMPEROR-PRESERVED clinical trials Boehringer Ingelheim
10126Wataru FukuokayaThe Jikei University School of MedicineHeterogeneous treatment effects of cabazitaxel in patients with castration-resistant prostate cancer Sanofi
10137, 9844Mariam KhayretdinovaBrainify.AIPredicting Placebo Response in Major Depressive Disorder on Clinical Trials Data Using Artificial Intelligence (AI)/Machine Learning (ML) on Clinical Data Takeda, Lilly, Lundbeck, Pfizer Inc., Johnson & Johnson
10138Issa DahabrehHarvard T. H. Chan School of Public HealthDevelopment of statistical methods for comparison of the efficacy of anticoagulants in non-valvular atrial fibrillation Daiichi Sankyo, Inc., Boehringer Ingelheim
10146Yuki MiyaiNagoya University HospitalImpact of Body Mass Index on Survival and Response in Cancer Patients Treated with Immune Checkpoint Inhibitors Project Data Sphere, ONO, Roche, AstraZeneca
10151Anthony WillemsUniversity GhentThe Impact of Sex, Age and Race on the Immunogenicity of Meningococcal Serogroup B Vaccination in Healthy Infants, Children, Adolescents and Young Adults: A Systematic Review and Meta-Analysis Pfizer Inc.
10155Brian GilletteDroice LabsDeveloping approaches to accelerate clinical trials using real world data (RWD) from electronic health records (EHR) Lilly, Takeda, Daiichi Sankyo, Inc.
10158Si-Cong MaThe First Affiliated Hospital of Sun Yat-Sen UniversityBiomarker-based strategies to enhance efficacy and reduce toxicity in lung cancer immunotherapy Roche
10200Dafne CapelusnikCare and Public Health Research Institute (CAPHRI), Maastricht UniversityAssessment of peripheral arthritis and related disease activity measurement instruments in spondyloarthritis Lilly, UCB, Johnson & Johnson, Pfizer Inc., AbbVie
10204Yanguang CaoUniversity of North Carolina at Chapel HillIdentifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Imatinib in Treatment of Chronic Myeloid Leukemia Pfizer Inc., Takeda
10273Andrea WiencierzDepartment of Clinical Research, University of Basel, University HospitalTransPALLAS study request_Vetter_209-C Alliance Foundation Trials, LLC (AFT)
10279Laetitia de Abreu NunesPragmatic Clinical Trials Units, Queen Mary University of LondonExamining statistical methods that leverage the hierarchical structure of adverse events for signal detection in randomised controlled trials Pfizer Inc., Biogen
10290Jeffrey BowerSana Health, INC.Anchor Based Minimal Clinical Important Difference calculation for the Neuropathic Pain Inventory Scale Pfizer Inc.
10291Chanho LeeYonsei University College of MedicineEffects of ezetimibe on clinical outcomes in patient with idiopathic pulmonary fibrosis (IPF) Boehringer Ingelheim
10293Joao Pedro FERREIRAFaculty of Medicine of Porto University Effect of Empagliflozin on Blood Pressure in Acute Heart Failure Boehringer Ingelheim
10313linsen yeThe Third Affiliated Hospital,Sun Yat-Sen UniversityEffect of liver lipid deposition on the treatment of atezolizumab plus bevacizumab: a retrospective study based on the IMBrave150 Roche
10317Kelley KidwellUniversity of Michigan School of Public HealthSeamless Design for Multiple Endpoints for Drug Development in Rare Diseases Using Gaussian Copula Model in Bayesian Framework : a case study from Hunter syndrome Takeda
10332Raphaèle Seror Immunology of Viral Infections and Autoimmune Diseases, INSERMRetrospective validation of the Sjögren's Tool for Assessing Response (STAR) as a primary endpoint for response to treatment in Primary Sjögren's Syndrome Servier
10360Javier CalvoUniversidad de Costa RicaIdentifying Clinical Predictors of Weight Loss in Older Adults with Diabetes: Insights from SURPASS Clinical Trials Lilly
10381Neeraj NarulaHamilton Health SciencesImpact of Concomitant Steroid Use on Adverse Events in Ulcerative Colitis Clinical Trials Johnson & Johnson, AbbVie, Takeda, Pfizer Inc.
10390Aaron MansfieldMayo ClinicComparison of the transcriptomic profiles of small cell lung cancer (SCLC) patients who are younger or have never smoked AstraZeneca
10391You-Shan FengUniversitätsklinikum TübingenPsychometric properties and scoring approaches for the EuroQol-5 dimension-5 level (EQ-5D-5L) Psoriasis-specific questions Lilly
10403Andreas MeidHeidelberg University Hospital – Medical Clinic (Krehl-Klinik) Internal Medicine IX – Dept. of Clinical Pharmacology & Pharmacoepidemiology, Im Neuenheimer Feld 410 , 69120 HeidelbergTREND-RIVIVAL - Trial results extension and disease course modelling for real-world evidence and valid inferences in the post-approval phase Project Data Sphere, Takeda
10404Marco Sanduzzi ZamparelliBCLC group, Liver Unit. Hospital Clinic of BarcelonaEffect of PPIs (proton-pump inhibitors) on treatment efficacy in patients with hepatocellular carcinoma Roche
10406Toby PillingerKing's College London (UK)Physiological effects of acute antidepressant treatment in psychiatric disorders: a systematic review and network meta-analysis Takeda, Lundbeck, Lilly, GlaxoSmithKline, Pfizer Inc.
10408Su SyonmezOrchard Therapeutics 245 Hammersmith Road, 3rd Floor London W6 8PW United KingdomNatural History Study of Patients With Mucopolysaccharidosis type IIIA (MPS IIIA) Takeda
10411João Pedro Ferreira Faculty of Medicine of Porto University, Porto, PortugalNSAIDs use and kidney outcomes in Heart Failure Boehringer Ingelheim
10441Amber SalterUT Southwestern Medical CenterExamining Heterogeneity in Response to Disease-Modifying Therapy in Multiple Sclerosis Roche, Sanofi, Biogen
10443Vitalay FominYAI INC.2024 DataWorks! Prize: Analyzing COVID-19 Drug Approval and Patient Response Using Historical Data Montreal Heart Institute, Salix Pharmaceuticals, HCor Research Institute, Certara, Hannover Medical School, Vaccines & Infectious Diseases Analytics Research Unit, Wits Health Consortium, Hospital Universitario Australia, The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, University of Washington, University of Minnesota, Johns Hopkins University
10450Sam RoystonReplica HealthMerging Big Datasets for Training Blood Glucose Prediction Models Jaeb Center for Health Research Foundation, Inc.
10462Nermin DiabMcMaster University Efficacy and safety of monoclonal antibodies in patients with uncontrolled asthma: a systematic review and network meta-analysis (2) GlaxoSmithKline, Johnson & Johnson, ImmPort (a data-sharing platform funded by the National Institutes of Health)
10463Chee LeeThe University of SydneyMeta-analysis of chemoimmunotherapy for epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) Bristol Myers Squibb
10464Maria PanagiotouUniversity of BernBlood Glucose Prediction Jaeb Center for Health Research Foundation, Inc.
10466Mia JovanovaUniversity of St. Gallen - School of MedicineTemporal dynamics of lifestyle factors and glycemic control among children with Type-1 Diabetes Jaeb Center for Health Research Foundation, Inc.
10467Lewis CarpenterArcturisMeasurement Error in Real-World Comparative Effectiveness Studies of Progression Free Survival in Multiple Myeloma Bristol Myers Squibb
10469Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityPredictors and prediction model for therapeutic outcomes in UC patients receiving Mirikizumab Lilly
10471Khandan KeyomarsiThe University of Texas MD Anderson Cancer CenterValidation of Predictive Molecular Biomarker for Predicting Response to Cyclin-Dependent Kinase 4 and 6 (CDK4/6) Inhibitors in Breast Cancer Using Data from PALOMA-2 and PALOMA-3 Studies Pfizer Inc.
10475jiabin caiassociate chief physician,Department of Liver Surgery and Transplantation of Zhongshan Hospital, Shanghai ChinaClinical and Molecular Characterization of Advanced Hepatocellular Carcinoma: Analysis of Therapeutic Responses Across Multiple Treatment Regimens Project Data Sphere, ImmPort (a data-sharing platform funded by the National Institutes of Health), Bayer, Sanofi
10486DongKeon YonCenter for Digital Health, Medical Science Research Institute, Kyung Hee UniversityValidation of Abrocitinib's efficacy and safety in moderate-to-severe atopic dermatitis across racial, ethnic, and skin type subgroups using machine learning models Pfizer Inc.
10487Surya BhattRespirAnalytics LLCResponse to placebo in patients with chronic obstructive pulmonary disease Boehringer Ingelheim, AstraZeneca
10491Jaeyoun ChoiUC San DiegoThe effect of frailty and old age on the efficacy and safety of biologics and small molecules in inflammatory bowel disease : A pooled analysis of individual patient data Takeda, AbbVie, Johnson & Johnson, Pfizer Inc., Lilly
10492Yongwen ZhouThe third affiliated hospital of SYSUReinforcement learning in automated insulin delivery Jaeb Center for Health Research Foundation, Inc.
10495Jonas SaalUniversity Hospital BonnInvestigation of the impact of serum electrolytes on the efficacy of immune-checkpoint blockade for solid cancer AstraZeneca, Roche, Lilly
10499Stefan KoudstaalErasmus Medical Center Rotterdam, NLPersonalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: the LIFE-Preserved Model Boehringer Ingelheim
10511Min Hyuk LimUNIST (Ulsan National Institute of Science and Technology)A study of establishing Machine Learning (ML) and Artificial Intelligence (AI) models for glucose dynamics. Jaeb Center for Health Research Foundation, Inc.
10540Alexander DrilonMemorial Sloan Kettering Cancer Center (MSKCC)Do patients with lung cancers positive for a RET gene alteration benefit from the addition of immunotherapy to chemotherapy? Lilly
10549Sumayyah PatelUniversity of LeedsCognition in Myeloma: A Systematic Review and Meta-analysis Takeda
10703Hong Jae ChonCHA Bundang Medical CenterA validation study of a machine learning model for predicting clinical benefit in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab. Roche
10706Neeraj NarulaHamilton Health SciencesAssessing the Impact of Disease Duration on the Likelihood of Healing in the Ileum and Colon in Crohn’s Disease AbbVie, Takeda, Johnson & Johnson
10707Zisheng ChenThe Affiliated Qingyuan Hospital (Qingyuan People's Hospital) of Guangzhou Medical UniversityThe Association between Liver Metastasis of Non-Small Cell Lung Cancer and Prognosis Based on Immunotherapy: A Secondary Summary analysis of Individual Patient Data from Randomized Trials Roche, AstraZeneca
10730David ByrneRCSI University of Medicine and Health SciencesCan network analysis be used to inform better treatment plans in anxiety and depression randomised trials? Assessing underlying assumptions and predicting treatment efficacy. Pfizer Inc., GlaxoSmithKline, Lundbeck, Lilly, Takeda
10732Bryan SaundersUniversity of Sao PauloSemaglutide for weight loss: Where is the weight loss coming from? A systematic review and meta-analysis Lilly
10735Andrew AchaiahGloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation TrustExploration of change in forced expiratory volume:forced vital capacity (FEV1:FVC) ratio from baseline to prognosticate clinical outcomes in idiopathic pulmonary fibrosis and predict treatment response to Nintedanib Boehringer Ingelheim
10740Thomas SchnitzerNorthwestern University Feinberg School of MedicinePredictors of Pain Response in Knee OA Lilly, Pfizer Inc., Regeneron
10749Dennis ShungYale School of MedicineDT1D: Digital Twin for Type 1 Diabetes Jaeb Center for Health Research Foundation, Inc.
10752 Anna Maria Claudia WägnerFundacion canaria Institudo de investigación sanitaria de Canarias (FCIISC)Exercise in Type 1 Diabetes Jaeb Center for Health Research Foundation, Inc.
10757Zhaojin ChenSaw Swee Hock School of Public Health, National University of SingaporeAnalyzing the Effectiveness of a New Cancer Treatment Using Historical Data in a Phase II Clinical Trial AstraZeneca
10783Kathryn ConnellyMonash University School of Clinical SciencesCan a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab GlaxoSmithKline
10785Jin Woo ChoiSeoul National University HospitalEvaluating the Efficacy and Safety of Systemic Treatments with Atezolizumab Plus Bevacizumab or Sorafenib in Patients with Hepatocellular Carcinoma and Localized Portal Vein Tumor Thrombosis Roche
10786Yuan HuangYale UniversityJointly modeling hypoglycemic event times and longitudinal glucose measurement with Brownian motion Jaeb Center for Health Research Foundation, Inc.
10816Shunan QiSenior doctor, Cancer Hospital Chinese Academy of Medical Sciences Analysis of Clinical Molecular Consistency and Treatment Benefit in lymphoma Sanofi, Takeda, Project Data Sphere
10827Ben CowlingThe University of Hong KongExploring Viral Shedding, Symptom Dynamics, and Antiviral Efficacy in Influenza Transmission Roche
10829Hollie PilkingtonLumanityComparison of statistical methodologies for comparing metastatic renal cell carcinoma treatments Pfizer Inc., Project Data Sphere
10832Jay ParkCore Clinical SciencesAssessing the Potential Effect of a New Diabetes Treatment in Canadian Populations Lilly
10835Surya BhattRespirAnalytics LLCResponse to Long Acting Bronchodilators by STaging of Airflow Obstruction by the Ratio (STAR) versus Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages of Chronic Obstructive Pulmonary Disease Boehringer Ingelheim
10836Jean-Charles Nault Université Paris CitéMachine learning based prediction of Survival and Progression to atezolizumab-bevacizumab in Hepatocellular Carcinoma (HCC) patients Roche
10842Youqi YangDepartment of Biostatistics, University of MichiganEstimating the Effect of Tirzepatide on Body Weight in Specific Subgroups: A Secondary Analysis Across Trials Lilly
10843Calvin KeUniversity Health NetworkEfficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials GlaxoSmithKline
10850Simon CauchemezInstitut PasteurEvaluating the impact of Baloxavir on dynamics of influenza within-host infection and within-household transmission Roche
10852Ramona Belfiore-OshanCritical Path InstituteDevelopment of an Artificial Intelligence/Machine Learning (AI/ML) model-based clinical trial simulation platform to better characterize Loss of Ambulation in Duchenne Muscular Dystrophy (DMD) Cure Duchenne
10855Stefan LeuchtDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of MunichSex differences in the efficacy and tolerability of antidepressants in the acute treatment of people with major depressive disorder: an individual-participant-data, dose-response, network meta-analysis Lundbeck, Lilly, GlaxoSmithKline, Pfizer Inc., Takeda
10856Jennifer LeesUniversity of GlasgowHow Multimorbidity Affects Cancer Treatment: Analyzing the Impact on Treatment Safety and Effectiveness in Clinical Trials AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, ONO, Pfizer Inc., Roche, Sanofi
10866William PhillipsUniversity of OttawaA longitudinal time-based assessment of toxicity prevalence and grade of targeted therapies and chemotherapy for treatment of advanced non-small cell lung cancer AstraZeneca, Boehringer Ingelheim, Pfizer Inc.
10870Sofia RamiroLeiden University Medical CenterDo fatty lesions explain why inflammation or erosions lead to new bone formation in axial spondyloarthritis (SpA)? Lilly, Pfizer Inc., UCB
10916Shane GoodwinWestern UniversityPredictability of biomarkers and disease activity indices for efficacy of advanced therapies in Crohn’s disease Johnson & Johnson, Takeda, AbbVie
10940Neeraj NarulaHamilton Health SciencesComparison of Onset of Efficacy of Therapies for Ulcerative Colitis Based on Patient Symptom Diary Data version 2 Johnson & Johnson, AbbVie, Takeda, Lilly, Pfizer Inc.
10954tianpei HongPeking University Third HospitalSodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels Boehringer Ingelheim
10956William HarrisFatty Acid Research InstituteExploring the Link Between Blood Fatty Acids and Cardiovascular Health Outcomes in the STRENGTH Study AstraZeneca
10960Yin Bun CheungDuke-NUS Medical School, Centre for Quantitative MedicineExtend previously approved access at CSDR (Research Proposal 12163): Novel approaches to the modelling of protective efficacy, immunity and infectious disease incidence: Malaria vaccination GlaxoSmithKline
10997Ricky TurgeonUniversity of British ColumbiaRe-analyzing Heart Failure Treatment Outcomes Based on Patient Preferences: A Study Using Data from Multiple Clinical Trials Boehringer Ingelheim
10999David CherneyUniversity Health NetworkKidney Outcomes with Sodium-glucose co-transporter-2 Inhibitors (SGLT2i) in Patients with type 2 diabetes (T2D) and Atherosclerotic cardiovascular disease (ASCVD): Insights from the VERTIS-CV Study within the SMART-C Framework Pfizer Inc.
11001João Pedro FerreiraFaculty of Medicine of Porto UniversitySodium-glucose co-transporter 2 inhibitors induced polycythemia and risk of cardiovascular events Boehringer Ingelheim, Johnson & Johnson
11003Vitalay FominNumenosPlacebo effect estimation utilizing large language model Lilly
11005Shane GoodwinWestern UniversityDisease and personal characteristics influencing the efficacy and safety of advanced therapies in moderate to severely active Crohn’s disease: Meta-analysis of individual patient data from randomized controlled trials Johnson & Johnson, Takeda, AbbVie
11010João Pedro FerreiraFaculty of Medicine of Porto UniversitySerum magnesium and the effect of empagliflozin in heart failure Boehringer Ingelheim
11011Zahari KassabovOpificio LtdStudy of diabetes metrics during exercise to understand how to improve glycemic control in patients Jaeb Center for Health Research Foundation, Inc.
11012Ali EzzatiUniversity of California, IrvinePredictors of Treatment Response to Acute and Preventive Medications in Migraine: Insights from the OVERCOME Study Lilly
11018Iveta JancigovaIQVIAOptimizing dose-finding in early oncology trials by utilizing information from multiple measures and simulations Daiichi Sankyo, Inc., Takeda
11020Joshua BakerUniversity of PennsylvaniaValidation of Disease Activity Measurement Thresholds for Arthritis Treatment Bristol Myers Squibb
11021Ahmad AbuhelwaUniversity of SharjahPredictors of therapeutic and adverse effects outcomes of acalabrutinib used in the treatment of chronic lymphocytic leukemia AstraZeneca
11037Alexandre BetourneCritical Path Institute Integration of Biogen Amyotrophic Lateral Sclerosis Data into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) Biogen
11038Andrew StrahsWave Life SciencesAnalysis of PRO-DMD-01 Functional Data to Inform Endpoints in Wave’s FORWARD-53 Study of WVE-N531 for Duchenne Muscular Dystrophy (DMD) Exon-53 Skipping Therapy Cure Duchenne
11041Alessio CortelliniDepartment of Surgery and CAncer, Imperial College London (UK)Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from adjuvant immunotherapy or best supportive in patients with resected early stage NSCLC (stage III): A post-hoc analysis of the Impower010 trial. Roche
11058Shane GoodwinWestern UniversityImpact of disease and patient specific factors on the efficacy and safety of advanced therapies in moderate-to-severe Ulcerative colitis: An individual patient data meta-analysis of multiple clinical trials Takeda, AbbVie, Johnson & Johnson, Lilly, Pfizer Inc.
11065Felicitas HuberWashington University in St. LouisExamining the Impact of Stigma in Migraine On Treatment Seeking Behaviors, Migraine Concealment, And Psychological Well-Being Lilly
11067Samuel MaidmanIcahn School of Medicine at Mount SinaiA pooled analysis of all Evinacumab studies assessing the effect of the drug on lipoprotein(a) levels Regeneron
11086Mingfang LiThe First Affiliated Hospital of Nanjing Medical UniversityImpact of Heart Failure Treatment and Empagliflozin on Stroke Risk in People with Atrial Fibrillation and Heart Failure: A Secondary Analysis from the EMPEROR-Preserved Study Boehringer Ingelheim
11088Neeraj NarulaHamilton Health SciencesDelayed Clinical Response to Adalimumab in Patients with Crohn’s Disease AbbVie
11090Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London (UK)Opioid use and the efficacy of immune checkpoint blockade in patients with extensive-stage small-cell lung cancer: A post hoc analysis of CASPIAN trial AstraZeneca
11121James GallowayCentre for Rheumatic Diseases, King's College LondonThe PARADOx (Progression Analysis in Rheumatoid Arthritis of raDiographic Outcomes) systematic review: Radiographic Progression and Treatment Tapering in Rheumatoid Arthritis AbbVie, Pfizer Inc., UCB
11130Joseph DoyleMIT Sloan School of ManagementUnderstanding the Impact of Diabetes Intervention Eligibility on Treatment Outcomes Lilly
11132Thomas PowlesBarts Cancer InstituteHealth related-quality of life (HRQoL) and defining immune related adverse events (irAE) in patients with renal cell carcinoma (RCC) offered adjuvant immune checkpoint inhibitor (ICI) Roche
11138Greg HapgoodMetro South HealthAssessing the Early Progression and Survival of Follicular Lymphoma Patients Compared to the General Population from the GALLIUM Trial Roche
11143Sujin LeeChung-ang UniversityThe Impact of Antibiotic Use on the Efficacy of Immune Checkpoint Inhibitors in Cancer Treatment: A Meta-Analysis Roche, Lilly
11162Morgan GramsNYU Grossman School of MedicineGlobal Study on How Chronic Kidney Disease Affects Cardiovascular Disease Risk Boehringer Ingelheim
11194Cade ShadboltUniversity of Melbourne Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials Lilly
11196Jeong Il YuDepartment of radiation oncology, Samsung Medical CenterEvaluating the Effectiveness of Proton Beam Radiotherapy Combined with Atezolizumab and Bevacizumab for Primary Liver Cancer with Portal Vein Invasion: The PORTAL Study Roche
11201Sicong MaNYU Langone HealthMarkers predicting immune-related adverse events of atezolizumab in lung cancer Roche
11242Dhiraj GambhireDaiichi SankyoDaiichi Sankyo Collaboration request_Pilot development of an artificial intelligence (AI) tool that can assist with reviewing clinical trial data Daiichi Sankyo, Inc.
11246Paolo NapoletanoUniversity of Milano-BicoccaPersonalized Blood Glucose Prediction Using Multimodal Real-Life Data and Artificial Intelligence Jaeb Center for Health Research Foundation, Inc.
11263Jacob OllechRabin Medical CenterIdentifying Factors That Predict Treatment Success in Patients with Chronic Pouchitis Using Vedolizumab Takeda
11275jahannaz dastgirREGENXBIO Inc. Rockville, MDAnalysis of functional data from Duchenne participants in a natural history study and the placebo control arm of an interventional clinical trial for the treatment of Duchenne in combination with other natural history data sets. Cure Duchenne
11277María S SoengasFundación Sector Público Estatal Centro Nacional Investigaciones Oncológicas Carlos III (CNIO)Improving Biomarker Identification for Melanoma Immunotherapy Using Ribonucleic Acid (RNA) Analysis Bristol Myers Squibb
11278Temiloluwa PrioleauEmory UniversityComparative analysis of publicly accessible diabetes datasets Jaeb Center for Health Research Foundation, Inc.
11281Carmen CastrilloAvidity BiosciencesAnalysis of progression on functional endpoints over time for participants in the PRO-DMD natural history database Cure Duchenne
11325Seong-Keun YooSamsung Medical CenterDevelopment of deep learning model predicting immune checkpoint inhibitor outcomes in urothelial bladder carcinoma Roche
11327Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityPredictors for therapeutic outcomes in patients with ulcerative colitis receiving Janus kinase inhibitor Alfasigma
11328Katie BechmanKing's College London Effects of obesity on treatment response to Janus kinase inhibitors (JAKi) in rheumatoid arthritis Alfasigma, Pfizer Inc., Lilly, AbbVie
11350Neeraj NarulaHamilton Health SciencesModified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) Thresholds as Predictors of Delayed Clinical Response to Upadacitinib in Patients with Crohn’s Disease AbbVie
11369Neeraj NarulaHamilton Health SciencesHistologic Activity as a Prognostic Marker in Post-Induction Ulcerative Colitis: A Post-Hoc Analysis of the VARSITY Trial Takeda
11370Takaaki MaekawaNational Defense Medical CollegeAnalysis of whether Plerixafor can be used as a single agent for rapid collection of blood stem cells in advance of potential radiation exposure Sanofi
11425Neeraj NarulaHamilton Health SciencesSerum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirkizumab in Ulcerative Colitis Lilly
11456Issa DahabrehHarvard T.H. Chan School of Public HealthAdvancing methods for applying the results of clinical trials to data from medical insurance claims for patients taking anti-coagulants for non-valvular atrial fibrillation Boehringer Ingelheim, Daiichi Sankyo, Inc.
11465Ullrich O. WenzelUniversity Medical Center Hamburg-EppendorfTirzepatide and Systolic Blood Pressure: An Individual Patient Metaanalysis Lilly
11487Gonzalo SperaTranslational Research in OncologyThe Association between Beta-blockers and Outcomes in Triple Negative Breast Cancer Roche
11561JOAN BUSNERSignant Health Psychometric analysis of the Children's Depression Rating Scale-Revised (CDRS-R) in a large international study of pediatric Major Depressive Disorder (MDD) Lundbeck
11690Soumyajit RoyUniversity Hospitals Cleveland Medical CenterTraining and Validation of PSA and Pain as Biomarkers and Causal Mediators in Metastatic Hormone Sensitive Prostate Cancer Bayer, Johnson & Johnson, Astellas
11694Jun MaoMemorial Sloan Kettering Cancer CenterTransPALLAS (NCT02513394) Alliance Foundation Trials, LLC (AFT)
11705Paolo RanziGruppo Per l'Informatica (GPI) S.p.A.Prediction of glucose dynamics by Bayesian modeling Jaeb Center for Health Research Foundation, Inc.